{
  "letters": 424107,
  "pages": 111,
  "meta": {
    "end_of_period": {
      "year": 2022,
      "month": 12
    },
    "company_name": "Celldex Therapeutics, Inc.",
    "major_industry": "Healthcare",
    "mentions_recent_mergers_and_acquisitions": {
      "value": true,
      "elements": [
        {
          "type": "merger_acquisition",
          "page": 28,
          "title": "Merger Agreement and Milestone Payment Obligations",
          "data": [
            {
              "key": "Acquisition Target",
              "value": "Kolltan (Acquired in 2016)"
            },
            {
              "key": "Settlement Agreement Date",
              "value": "July 15, 2022"
            },
            {
              "key": "Milestone Payment Obligation",
              "value": "Up to $65,000,000 as of December 31, 2022"
            },
            {
              "key": "Payment Methods",
              "value": "Cash, shares of common stock, or combination thereof"
            },
            {
              "key": "Risk of Dilution",
              "value": "Substantial dilution if payment is made in shares"
            },
            {
              "key": "Clinical Trial Milestone",
              "value": "Successful completion of a Phase 2 clinical trial of CDX-0159 or regulatory approval"
            },
            {
              "key": "Additional Financing Needs",
              "value": "May require raising additional capital if cash payment is elected"
            },
            {
              "key": "Regulatory Considerations",
              "value": "Dependence on FDA and EMA approvals and potential impact of U.S. federal tax reforms"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 73,
          "title": "Internal Control and Kolltan Settlement Details",
          "data": [
            {
              "key": "Internal Control Definition",
              "value": "A company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. It includes policies and procedures for record maintenance, ensuring authorized transactions, and preventing or detecting unauthorized asset use."
            },
            {
              "key": "Critical Audit Matters",
              "value": "Discussion of critical audit matters highlighting the auditor's significant effort in assessing the treatment of future milestone payments related to the Kolltan settlement, addressing complex judgments and subjectivity."
            },
            {
              "key": "Acquisition Details",
              "value": "On November 29, 2016, the Company acquired all of the share and debt interests of Kolltan in exchange for 1,217,200 shares and contingent consideration of up to $172.5 million, dependent on achieving development, regulatory, or sales-based milestones."
            },
            {
              "key": "Litigation and Settlement",
              "value": "A dispute arose regarding the characterization of milestone payments, leading to litigation filed on August 18, 2020, and a subsequent settlement agreement executed on July 15, 2022, which replaced the original contingent consideration with binding payment obligations."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 85,
          "title": "Fair Value Measurements and Contingent Consideration Disclosures",
          "data": [
            {
              "key": "Financial Assets and Liabilities (2022)",
              "value": "Financial Assets and Liabilities Fair Value Measurement as of December 31, 2022; assets include money market funds, cash equivalents, and marketable securities classified as Level 2; liabilities include a Kolltan acquisition contingent consideration with undefined amounts"
            },
            {
              "key": "Financial Assets and Liabilities (2021)",
              "value": "Fair Value Hierarchy as of December 31, 2021 showing total assets of $395,327,000 and contingent consideration liability of $6,862,000 classified as Level 3"
            },
            {
              "key": "Contingent Consideration Movement",
              "value": "Other Liabilities: Contingent Consideration table shows balance of $6,862 at December 31, 2021, fair value adjustment of $(6,862), resulting in a zero balance at December 31, 2022"
            },
            {
              "key": "Fair Value Remeasurement Gain",
              "value": "$6.9 million gain recorded during the year ended December 31, 2022 due to deprioritization of the CDX-1140 program"
            },
            {
              "key": "Acquisition Reference",
              "value": "Kolltan acquisition (2016); contingent consideration liabilities relate to this transaction"
            },
            {
              "key": "Valuation Method",
              "value": "Level 3 liabilities measured primarily using an income approach with significant unobservable inputs (probability of success, discount rates, timing of milestone payments)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 93,
          "title": "Kolltan Acquisition",
          "data": [
            {
              "key": "Acquisition Date",
              "value": "November 29, 2016"
            },
            {
              "key": "Target Company",
              "value": "Kolltan, a clinical-stage biopharmaceutical company"
            },
            {
              "key": "Transaction Structure",
              "value": "Acquired all share and debt interests in exchange for 1,217,200 shares of the Company’s common stock plus contingent consideration"
            },
            {
              "key": "Contingent Consideration",
              "value": "Up to $172.5 million payable in cash, in shares of common stock, or a combination of both"
            },
            {
              "key": "Milestone Basis",
              "value": "Contingent consideration is based on achieving development, regulatory approval, or sales-based milestones (Kolltan Milestones) for the discontinued CDX-0158 program"
            },
            {
              "key": "Litigation and Settlement",
              "value": "Dispute arose when SRS objected to milestone characterization; Complaint filed on August 18, 2020; Settlement term sheet dated June 20, 2022; Settlement Agreement executed on July 15, 2022; Joint dismissal with prejudice filed on July 19, 2022"
            },
            {
              "key": "Settlement Payments",
              "value": "Initial Payment of $15.0 million upon execution of the Settlement Agreement and an additional $15.0 million payable upon successful completion of a Phase 2 Clinical Trial of barzolvolimab, subject to a $2.5 million contractual credit"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 94,
          "title": "Merger Agreement: Payment Milestones and Contingent Consideration",
          "data": [
            {
              "key": "Regulatory Approval Payment",
              "value": "$52.5 million payable upon first regulatory approval by the US FDA, EMA, or their successor"
            },
            {
              "key": "Contingent Consideration Replacement",
              "value": "Replaces contingent milestone obligations previously up to $172.5 million in the Merger Agreement"
            },
            {
              "key": "Settlement Agreement Releases",
              "value": "Mutual releases of all claims relating to or arising out of the Merger Agreement, including litigation claims"
            },
            {
              "key": "Initial Payment",
              "value": "Paid in cash in July 2022"
            },
            {
              "key": "Future Milestone Payments",
              "value": "Related to the barzolvolimab program (subject to litigation) recorded under ASC 450 when probable; payable in cash, stock, or a combination at the Company’s option"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 98,
          "title": "Exhibit 2.1 - Agreement and Plan of Merger",
          "data": [
            {
              "key": "No.",
              "value": "2.1"
            },
            {
              "key": "Description",
              "value": "Agreement and Plan of Merger, dated as of November 1, 2016, by and among Kolltan Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Connemara Merger Sub 1 Inc. and Connemara Sub 2 LLC."
            },
            {
              "key": "Form and SEC File No.",
              "value": "8-K (000-15006)"
            },
            {
              "key": "Exhibit No.",
              "value": "21"
            },
            {
              "key": "SEC Filing Date",
              "value": "11/1/16"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 98,
          "title": "Exhibit 2.2 - Merger Binding Settlement Term Sheet",
          "data": [
            {
              "key": "No.",
              "value": "2.2"
            },
            {
              "key": "Description",
              "value": "Merger Binding Settlement Term Sheet, dated June 20, 2022, by and between Shareholder Representatives Services LLC, solely in its capacity as Stockholders"
            },
            {
              "key": "Form and SEC File No.",
              "value": "8-K (000-15006)"
            },
            {
              "key": "Exhibit No.",
              "value": "10.1"
            },
            {
              "key": "SEC Filing Date",
              "value": "6/23/22"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 98,
          "title": "Exhibit 2.3 - Confidential Settlement Agreement and Mutual Release",
          "data": [
            {
              "key": "No.",
              "value": "2.3"
            },
            {
              "key": "Description",
              "value": "Confidential Settlement Agreement and Mutual Release, dated July 15, 2022, by and between Shareholder Representatives Services LLC, solely in its capacity as Stockholders Representative, and Celldex Therapeutics, Inc."
            },
            {
              "key": "Form and SEC File No.",
              "value": "8-K (000-15006)"
            },
            {
              "key": "Exhibit No.",
              "value": "10.1"
            },
            {
              "key": "SEC Filing Date",
              "value": "7/18/22"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 98,
          "title": "Exhibit 3.1 - Third Restated Certificate of Incorporation",
          "data": [
            {
              "key": "No.",
              "value": "3.1"
            },
            {
              "key": "Description",
              "value": "Third Restated Certificate of Incorporation"
            },
            {
              "key": "Form and SEC File No.",
              "value": "S-4 (333-59215)"
            },
            {
              "key": "Exhibit No.",
              "value": "3.1"
            },
            {
              "key": "SEC Filing Date",
              "value": "7/16/98"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 98,
          "title": "Exhibit 3.2 - Certificate of Amendment of Third Restated Certificate of Incorporation",
          "data": [
            {
              "key": "No.",
              "value": "3.2"
            },
            {
              "key": "Description",
              "value": "Certificate of Amendment of Third Restated Certificate of Incorporation"
            },
            {
              "key": "Form and SEC File No.",
              "value": "S-4 (333-59215)"
            },
            {
              "key": "Exhibit No.",
              "value": "3.1"
            },
            {
              "key": "SEC Filing Date",
              "value": "7/16/98"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 98,
          "title": "Exhibit 3.3 - Second Certificate of Amendment of Third Restated Certificate of Incorporation",
          "data": [
            {
              "key": "No.",
              "value": "3.3"
            },
            {
              "key": "Description",
              "value": "Second Certificate of Amendment of Third Restated Certificate of Incorporation"
            },
            {
              "key": "Form and SEC File No.",
              "value": "S-4 (333-59215)"
            },
            {
              "key": "Exhibit No.",
              "value": "3.2"
            },
            {
              "key": "SEC Filing Date",
              "value": "7/16/98"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 98,
          "title": "Exhibit 3.4 - Third Certificate of Amendment of Third Restated Certificate of Incorporation",
          "data": [
            {
              "key": "No.",
              "value": "3.4"
            },
            {
              "key": "Description",
              "value": "Third Certificate of Amendment of Third Restated Certificate of Incorporation"
            },
            {
              "key": "Form and SEC File No.",
              "value": "10-Q (000-15006)"
            },
            {
              "key": "Exhibit No.",
              "value": "3.1"
            },
            {
              "key": "SEC Filing Date",
              "value": "5/10/02"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 98,
          "title": "Exhibit 3.5 - Fourth Certificate of Amendment of Third Restated Certificate of Incorporation",
          "data": [
            {
              "key": "No.",
              "value": "3.5"
            },
            {
              "key": "Description",
              "value": "Fourth Certificate of Amendment of Third Restated Certificate of Incorporation"
            },
            {
              "key": "Form and SEC File No.",
              "value": "8-K (000-15006)"
            },
            {
              "key": "Exhibit No.",
              "value": "3.1"
            },
            {
              "key": "SEC Filing Date",
              "value": "3/11/08"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 98,
          "title": "Exhibit 3.6 - Fifth Certificate of Amendment of Third Restated Certificate of Incorporation",
          "data": [
            {
              "key": "No.",
              "value": "3.6"
            },
            {
              "key": "Description",
              "value": "Fifth Certificate of Amendment of Third Restated Certificate of Incorporation"
            },
            {
              "key": "Form and SEC File No.",
              "value": "8-K (000-15006)"
            },
            {
              "key": "Exhibit No.",
              "value": "3.2"
            },
            {
              "key": "SEC Filing Date",
              "value": "3/11/08"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 98,
          "title": "Exhibit 3.7 - Sixth Certificate of Amendment of Third Restated Certificate of Incorporation",
          "data": [
            {
              "key": "No.",
              "value": "3.7"
            },
            {
              "key": "Description",
              "value": "Sixth Certificate of Amendment of Third Restated Certificate of Incorporation"
            },
            {
              "key": "Form and SEC File No.",
              "value": "10-Q (000-15006)"
            },
            {
              "key": "Exhibit No.",
              "value": "3.7"
            },
            {
              "key": "SEC Filing Date",
              "value": "11/10/08"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 105,
          "title": "Anti-Takeover Provisions",
          "data": [
            {
              "key": "Overview",
              "value": "Provisions in the certificate of incorporation, by-laws, and under Delaware law designed to discourage change of control, even if such a transaction might offer a substantial premium to stockholders."
            },
            {
              "key": "Special Meetings",
              "value": "Special meetings can only be called by the chair of the board, the president, secretary, or the board of directors, thereby limiting unauthorized calls for meetings."
            },
            {
              "key": "Advance Notice Requirements",
              "value": "Stockholder proposals for nominations or other business at annual meetings must be submitted in advance and meet specific procedural criteria, potentially delaying actions favored by a majority."
            },
            {
              "key": "Delaware Business Combination Statute",
              "value": "Section 203 of Delaware General Corporation Law restricts business combinations with any 'interested stockholder' for three years unless approved by the board or through a prescribed process. A business combination includes mergers, consolidations, or the sale of more than 10% of assets."
            },
            {
              "key": "Exclusive Forum Selection",
              "value": "By-laws designate the Court of Chancery of Delaware (or an alternative Delaware forum) for internal corporate claims, and U.S. federal district courts for securities-related claims."
            },
            {
              "key": "Transfer Agent",
              "value": "Computershare Trust Company, N.A. serves as the transfer agent and registrar for common stock."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_leadership_changes": {
      "value": false,
      "elements": []
    },
    "has_layoffs": {
      "value": false,
      "elements": []
    },
    "has_executive_compensation": {
      "value": true,
      "elements": [
        {
          "type": "executive_compensation",
          "page": 89,
          "title": "Stock Options Activity Summary",
          "data": [
            {
              "key": "Options outstanding at December 31, 2021",
              "value": "4,077,667"
            },
            {
              "key": "Granted",
              "value": "1,620,000"
            },
            {
              "key": "Exercised",
              "value": "(458,254)"
            },
            {
              "key": "Canceled",
              "value": "(153,751)"
            },
            {
              "key": "Options outstanding at December 31, 2022",
              "value": "5,085,662"
            },
            {
              "key": "Options vested and expected to vest at December 31, 2022",
              "value": "4,970,769"
            },
            {
              "key": "Options exercisable at December 31, 2022",
              "value": "2,100,491"
            },
            {
              "key": "Shares available for grant under the 2021 Plan",
              "value": "1,837,968"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 90,
          "title": "Stock-Based Compensation Expense by Department",
          "data": [
            {
              "key": "Research and development",
              "value": "$8.1 million"
            },
            {
              "key": "General and administrative",
              "value": "$7.5 million"
            },
            {
              "key": "Total stock-based compensation expense",
              "value": "$15.6 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 90,
          "title": "Stock Options Valuation Metrics",
          "data": [
            {
              "key": "Expected stock price volatility",
              "value": "90 - 97% / 97 - 98% / 91 - 98%"
            },
            {
              "key": "Expected option term",
              "value": "6.0 Years"
            },
            {
              "key": "Risk-free interest rate",
              "value": "1.7 - 4.2% / 0.8 - 1.4% / 0.5 - 0.7%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 97,
          "title": "Table of Contents - Executive Governance & Compensation Items",
          "data": [
            {
              "key": "Item 10",
              "value": "DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE. Information provided in the definitive Proxy Statement for the 2023 Annual Meeting of Stockholders under sections including “Information Regarding Our Current Directors and Executive Officers,” “Delinquent Section 16(a) Reports,” “Code of Business Conduct and Ethics” and “The Board of Directors and Its Committees.”"
            },
            {
              "key": "Item 11",
              "value": "EXECUTIVE COMPENSATION. Details will be provided in the 2023 Proxy Statement under “Executive Compensation” and “Compensation Committee Interlocks and Insider Participation.”"
            },
            {
              "key": "Additional Items",
              "value": "Items 12 to 14 relate to SECURITY OWNERSHIP, RELATED TRANSACTIONS, and PRINCIPAL ACCOUNTING FEES and are incorporated by reference, with information provided via the 2023 Proxy Statement if not filed with the SEC within 120 days after the fiscal year end."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 101,
          "title": "Exhibit Index – Employment Agreements, Plan Forms, and XBRL Documents",
          "data": [
            {
              "key": "Employment Agreements",
              "value": "Amended and Restated Employment Agreement (dated July 1, 2021) between Celldex Therapeutics, Inc. and Margo Heath-Chiozzi, M.D.; Various Employment Agreements for Elizabeth Crowley, Richard Wright, Ph.D., and Diane Young, M.D."
            },
            {
              "key": "Plan Forms",
              "value": "Celldex Therapeutics, Inc. 2021 Plan Forms (Stock Awards and Options) and 2008 Plan Forms"
            },
            {
              "key": "XBRL Documents",
              "value": "101.INS-104: XBRL Related Documents including Inline XBRL Taxonomy Extension Schema (101.SCH), Calculation (101.CAL), Definition Linkbase (101.DEF), Label Linkbase (101.LAB), and Presentation (101.PRE); certain confidential portions redacted"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 102,
          "title": "Item 16. FORM 10-K SUMMARY",
          "data": [
            {
              "key": "Confidentiality Notice",
              "value": "Table of Contents material, which if publicly disclosed would be competitively harmful and is customarily treated as private by Celldex Therapeutics, Inc."
            },
            {
              "key": "Management Contract/Compensation",
              "value": "Indicates a management contract or compensation plan, contract or arrangement."
            },
            {
              "key": "Form 10-K Summary",
              "value": "None. 100"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_rnd_investment_numbers": {
      "value": true,
      "elements": [
        {
          "type": "rnd_investment",
          "page": 5,
          "title": "Table of Contents & Business Overview",
          "data": [
            {
              "key": "Company Name",
              "value": "Celldex Therapeutics, Inc."
            },
            {
              "key": "Business Focus",
              "value": "Developing therapeutic monoclonal and bispecific antibodies for diseases with inadequate treatments"
            },
            {
              "key": "Primary Drug Candidate",
              "value": "Barzolvolimab (CDX-0159)"
            },
            {
              "key": "Clinical Development",
              "value": "Phase 1b and Phase 2 studies in mast cell driven diseases including chronic urticarias, prurigo nodularis, and eosinophilic esophagitis"
            },
            {
              "key": "R&D Initiatives",
              "value": "Continued research and development of antibody-based therapeutics and expansion via next-generation bispecific antibody platform"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 6,
          "title": "Clinical Trial Update: Barzolvolimab in Mast Cell–Driven Diseases",
          "data": [
            {
              "key": "Study Design",
              "value": "Randomized, double-blind, placebo-controlled trial; Phase 1a study in healthy subjects and Phase 1b study in CSU patients."
            },
            {
              "key": "Drug",
              "value": "Barzolvolimab"
            },
            {
              "key": "Indications",
              "value": "Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), and potential applications in other mast cell-driven conditions."
            },
            {
              "key": "Phase 1a Details",
              "value": "Completed in June 2020 with 32 healthy subjects; evaluated a single intravenous infusion at doses of 0.3, 1.0, 3.0, or 9.0 mg/kg."
            },
            {
              "key": "Safety and Pharmacodynamics",
              "value": "Favorable safety profile with profound and durable reductions in plasma tryptase, indicative of systemic mast cell suppression."
            },
            {
              "key": "Expansion of Program",
              "value": "Data supported program expansion into mast cell–driven diseases, with ongoing Phase 1 studies in CSU/CIndU and other indications, and Phase 2 evaluation for a subcutaneous formulation."
            },
            {
              "key": "Phase 1b Update",
              "value": "Initiated in October 2020 for CSU with enrollment complete as of November 29, 2022; included 45 patients with moderate to severe CSU refractory to antihistamines."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 7,
          "title": "Phase 2 Study Results and Study Design for Barzolvolimab in CSU",
          "data": [
            {
              "key": "Efficacy - Mean Reduction in UAS7",
              "value": "67% in 1.5 mg/kg (n=8), 67% in 3.0 mg/kg (n=9), 82% in 4.5 mg/kg (n=9) at week 12"
            },
            {
              "key": "Efficacy - Complete Response (UAS7=0)",
              "value": "57% in 1.5 mg/kg, 44% in 3.0 mg/kg, 67% in 4.5 mg/kg at week 12"
            },
            {
              "key": "Disease Control - Well-controlled (UCT ≥ 12)",
              "value": "75% in 1.5 mg/kg, 63% in 3.0 mg/kg, 89% in 4.5 mg/kg at week 12"
            },
            {
              "key": "Response Durability",
              "value": "High maintenance of complete response through 24 weeks; 88% for lower doses and 100% for 4.5 mg/kg group"
            },
            {
              "key": "Onset of Response",
              "value": "Rapid onset observed as early as 1 week after first dose with prolonged symptom control up to 24 weeks"
            },
            {
              "key": "Safety and Tolerability",
              "value": "Well tolerated; most adverse events (hair color changes, COVID-19, headache, neutropenia, UTIs) were mild/moderate and resolved; one serious event (salmonella gastroenteritis) not related to treatment"
            },
            {
              "key": "Mast Cell Depletion Indicator",
              "value": "Tryptase suppression correlated with symptom improvement, affirming the impact of mast cell depletion"
            },
            {
              "key": "Phase 2 Study Design",
              "value": "Randomized, double-blind, placebo-controlled Phase 2 study in CSU patients; approx 168 patients, 75 sites across 9 countries; dosing arms include barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks vs placebo during a 16-week phase, followed by a 36-week active treatment and 24-week follow-up phase"
            },
            {
              "key": "Primary Endpoint",
              "value": "Mean change from baseline to week 12 in UAS7"
            },
            {
              "key": "Secondary Endpoints",
              "value": "Included ISS7, HSS7, and AAS7 assessments and overall safety profiles"
            },
            {
              "key": "Timeline for Enrollment and Data Reporting",
              "value": "Enrollment projected to complete by end of Q3 2023 with topline results expected late 2023 or Q1 2024"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 9,
          "title": "Clinical Trial Results Update and Phase 2 Study Announcement",
          "data": [
            {
              "key": "Presentation Date",
              "value": "December 2022"
            },
            {
              "key": "Indications",
              "value": "Cold Urticaria and Symptomatic Dermographism"
            },
            {
              "key": "Dose Cohorts",
              "value": "3.0 mg/kg and 1.5 mg/kg barzolvolimab"
            },
            {
              "key": "3.0 mg/kg Cohort - Long Term Follow Up",
              "value": "14 patients (6 cold urticaria, 8 symptomatic dermographism) with data collected from week 12 through week 36; 10 of 14 had complete control at week 12"
            },
            {
              "key": "3.0 mg/kg Cohort - 36 Week Outcomes",
              "value": "Most patients experienced a return of symptoms between weeks 12 and 36; 2 remained provocation negative at 36 weeks and 4 had well controlled disease (UCT ≥12)"
            },
            {
              "key": "Biomarker Observations",
              "value": "Serum tryptase returned to pretreatment levels, skin mast cells recovered at a slower rate, and tissue KIT signaling (approximated by SCF levels) reactivated around 18 weeks post dosing"
            },
            {
              "key": "1.5 mg/kg Cohort Results",
              "value": "10 patients treated (9 evaluable) in cold urticaria; 100% achieved complete response by provocation testing; rapid onset with 6 of 9 achieving complete response within one week; median duration of response was 51+ days; improvements confirmed by UCT scores"
            },
            {
              "key": "Safety Profile",
              "value": "Barzolvolimab was generally well tolerated with no new treatment emergent adverse events; mild, transient, asymptomatic decreases in hemoglobin and WBC observed but generally within normal range"
            },
            {
              "key": "Phase 2 Study Announcement",
              "value": "In July 2022, first patient dosed in a Phase 2 study evaluating multiple dosing regimens in patients with CIndU (including ~90 patients with cold urticaria and ~90 with symptomatic dermographism) across about 85 sites in 12 countries; study includes a placebo-controlled phase and an open label extension"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 10,
          "title": "Barzolvolimab Clinical Development Updates",
          "data": [
            {
              "key": "Indications",
              "value": "Prurigo Nodularis (PN) and Eosinophilic Esophagitis (EoE)"
            },
            {
              "key": "Clinical Trials",
              "value": "Phase 1b study in PN (intravenous), Phase 2 study in EoE (subcutaneous), and a Phase 1 study in healthy volunteers for subcutaneous formulation"
            },
            {
              "key": "Enrollment Details",
              "value": "PN enrollment closed at 24 patients; EoE study planned to initiate in the first half of 2023"
            },
            {
              "key": "Manufacturing & Process Update",
              "value": "Completed activities for subcutaneous formulation; manufacturing process transferred to a contract manufacturing organization in 2022"
            },
            {
              "key": "Toxicology Findings",
              "value": "Non-human primate study indicated dose-dependent effects on spermatogenesis with full recovery during a one-year recovery period"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 24,
          "title": "Table of Contents and R&D Outlook",
          "data": [
            {
              "key": "Research and Development Investment",
              "value": "A significant portion of our operating expenses will continue to be related to research and development in 2023 as we advance our drug candidates through clinical development."
            },
            {
              "key": "Incorporation",
              "value": "Delaware"
            },
            {
              "key": "Company Website",
              "value": "http://www.celldex.com"
            },
            {
              "key": "SEC Website",
              "value": "http://www.sec.gov"
            },
            {
              "key": "Investor Documents",
              "value": "Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, Code of Conduct and Business Ethics, and other related filings under Section 13(a) or 15(d) of the Exchange Act."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 54,
          "title": "Management’s Discussion and Analysis of R&D Pipeline and Clinical Trials",
          "data": [
            {
              "key": "Company Focus",
              "value": "We are a biopharmaceutical company dedicated to developing therapeutic monoclonal and bispecific antibodies addressing diseases with unmet treatment needs, focusing on inflammatory diseases and oncology."
            },
            {
              "key": "Key Drug Candidate",
              "value": "Barzolvolimab (also referred to as CDX-0159) is a monoclonal antibody targeting the KIT receptor, currently studied in multiple mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), cold urticaria, and symptomatic dermographism."
            },
            {
              "key": "Pipeline Expansion",
              "value": "The company is also advancing a next-generation bispecific antibody platform to support pipeline growth with additional candidates for inflammatory diseases and oncology."
            },
            {
              "key": "Clinical Trial Durations",
              "value": "According to the provided table, Phase 1 trials are expected to take 1-2 years, while Phase 2 and Phase 3 trials are anticipated to last between 1-5 years each."
            },
            {
              "key": "R&D Investment Uncertainty",
              "value": "The duration and cost of clinical trials are subject to significant uncertainty, influenced by factors such as trial protocol variations and patient enrollment numbers."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 55,
          "title": "Research and Development Expenses by Program",
          "data": [
            {
              "key": "R&D Strategy Overview",
              "value": "The document details the process of testing drug candidates through preclinical studies and multiple clinical trials, highlighting the uncertainties in development timelines and outcomes. It emphasizes a diversified pipeline approach to manage risks and outlines potential collaborative agreements which may influence project timelines and capital requirements."
            },
            {
              "key": "Barzolvolimab/Anti-KIT Program",
              "value": "2022: 51220, 2021: 24395, 2020: 8444"
            },
            {
              "key": "CDX-585",
              "value": "2022: 9793, 2021: 7133, 2020: 0"
            },
            {
              "key": "CDX-527",
              "value": "2022: 2012, 2021: 3619, 2020: 8840"
            },
            {
              "key": "CDX-1140 and CDX-301",
              "value": "2022: 3992, 2021: 5439, 2020: 10948"
            },
            {
              "key": "Other Programs",
              "value": "2022: 15241, 2021: 12725, 2020: 14302"
            },
            {
              "key": "Total R&D Expense",
              "value": "2022: 82258, 2021: 53311, 2020: 42534"
            },
            {
              "key": "Table Summary",
              "value": "The table shows significant growth in total R&D expenses from $42.5M in 2020 to $82.3M in 2022, with notable increases in the Barzolvolimab/Anti-KIT Program and varying trends across other programs."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 56,
          "title": "Clinical Development Programs – Barzolvolimab (CDX-0159)",
          "data": [
            {
              "key": "drug_name",
              "value": "Barzolvolimab (CDX-0159)"
            },
            {
              "key": "description",
              "value": "Humanized monoclonal antibody that binds receptor tyrosine kinase KIT to inhibit mast cell activity by blocking SCF binding and KIT dimerization."
            },
            {
              "key": "mechanism_of_action",
              "value": "Inhibits KIT activity, leading to decreased mast cell growth, differentiation, survival, chemotaxis and degranulation."
            },
            {
              "key": "clinical_trials_phase1a",
              "value": "Randomized, double-blind, placebo-controlled, single ascending dose study in healthy subjects with 0.3, 1.0, 3.0, and 9.0 mg/kg doses."
            },
            {
              "key": "clinical_trials_phase1b",
              "value": "Multi-center Phase 1b study in CSU patients enrolled in October 2020 evaluating multiple ascending doses as add-on to antihistamines."
            },
            {
              "key": "future_development",
              "value": "Phase 2 studies in CSU and CIndU ongoing; additional studies in prurigo nodularis and planned Phase 2 in eosinophilic esophagitis in H1/ H2 antihistamine refractory patients."
            },
            {
              "key": "administration_routes",
              "value": "Intravenous in Phase 1 studies; subcutaneous formulation developed for Phase 2 studies."
            },
            {
              "key": "target_diseases",
              "value": "Mast cell-driven diseases including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and potentially dermatologic, respiratory, allergic, gastrointestinal, and ophthalmic conditions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 57,
          "title": "Interim Data from CSU Study",
          "data": [
            {
              "key": "Report Date",
              "value": "February 2023"
            },
            {
              "key": "Data Cutoff Date",
              "value": "November 29, 2022"
            },
            {
              "key": "Total Enrollment",
              "value": "45 patients with moderate to severe CSU refractory to antihistamines"
            },
            {
              "key": "Dose Groups",
              "value": "barzolvolimab 0.5 mg/kg (n=9), 1.5 mg/kg (n=8), 3.0 mg/kg (n=9), 4.5 mg/kg (n=9); placebo (n=10)"
            },
            {
              "key": "Efficacy Outcomes",
              "value": "Mean UAS7 reduction at week 12: 67% for 1.5 mg/kg and 3.0 mg/kg groups, 82% for 4.5 mg/kg group; Complete response (UAS7=0) rates: 57% (1.5 mg/kg), 44% (3.0 mg/kg), 67% (4.5 mg/kg); Well-controlled disease (UCT ≥ 12): 75%, 63%, and 89% respectively"
            },
            {
              "key": "Response Duration and Follow-up",
              "value": "Rapid onset observed as early as 1 week; sustained responses maintained through up to 24 weeks in most patients"
            },
            {
              "key": "Safety Profile",
              "value": "Well tolerated with most adverse events being mild or moderate; common AEs include hair color changes, COVID-19, headache, neutropenia, and urinary tract infections; hematologic parameters remained largely within normal ranges"
            },
            {
              "key": "Additional Findings",
              "value": "Tryptase suppression noted, indicating mast cell depletion correlated with symptom improvement"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 58,
          "title": "Clinical Trial Overview for Barzolvolimab in Urticaria",
          "data": [
            {
              "key": "Phase 2 Study Initiation",
              "value": "In June 2022, the first patient was dosed in a Phase 2 study for Chronic Spontaneous Urticaria (CSU) despite antihistamine therapy."
            },
            {
              "key": "Study Design",
              "value": "Randomized, double-blind, placebo-controlled, parallel group study evaluating multiple dose regimens."
            },
            {
              "key": "Study Sites and Regions",
              "value": "Approximately 75 sites across 9 countries."
            },
            {
              "key": "Patient Enrollment",
              "value": "Approximately 168 patients randomized in a 1:1:1:1 ratio for different dosing arms."
            },
            {
              "key": "Dosing Regimens",
              "value": "Barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks, or placebo during a 16‑week placebo‐controlled phase, followed by a 36‑week active treatment phase and a 24‑week follow‐up."
            },
            {
              "key": "Primary and Secondary Endpoints",
              "value": "Primary endpoint: Mean change in Urticaria Activity Score over 7 days (UAS7) at week 12; Secondary endpoints include safety, ISS7, HSS7, and AAS7."
            },
            {
              "key": "Anticipated Enrollment Completion and Reporting",
              "value": "Enrollment expected to complete by end of Q3 2023 with topline data reporting late this year or in Q1 2024."
            },
            {
              "key": "Phase 1b Study in Chronic Inducible Urticaria (CIndU)",
              "value": "Initiated in December 2020 in Germany for patients refractory to antihistamines with a single dose (3 mg/kg) in ColdU or symptomatic dermographism; additional cohorts added in 2021 for cholinergic urticaria and a lower-dose cohort in ColdU."
            },
            {
              "key": "Efficacy and Safety Outcomes",
              "value": "For ColdU and SD cohorts, rapid and durable responses observed with 95% complete response rate and improvements in Urticaria Control Test scores as early as week 4; results published in November 2022."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 60,
          "title": "Clinical Development Update for Barzolvolimab",
          "data": [
            {
              "key": "Drug Name",
              "value": "Barzolvolimab"
            },
            {
              "key": "Dose Information",
              "value": "1.5 mg/kg and 3.0 mg/kg evaluated; 1.5 mg/kg shown to rapidly suppress serum tryptase"
            },
            {
              "key": "Indications",
              "value": "Cold Urticaria, Chronic Inducible Urticaria (CIndU), Prurigo Nodularis (PN), Eosinophilic Esophagitis (EoE)"
            },
            {
              "key": "Study Phases",
              "value": "Phase 1b study (cold urticaria) and planned/ongoing Phase 2 studies (CIndU and EoE); Phase 1b PN study initiated with enrollment closed at 24 patients"
            },
            {
              "key": "Trial Design",
              "value": "Randomized, double-blind, placebo-controlled, parallel group study; subcutaneous injections in Phase 2 with multiple dosing regimens"
            },
            {
              "key": "Patient Response",
              "value": "100% (19/19) complete response by provocation testing in cold urticaria patients in Phase 1b study"
            },
            {
              "key": "Study Endpoints",
              "value": "Primary endpoint: percentage of patients with a negative provocation test at week 12; Secondary endpoints: Critical Temperature Threshold (CTT), Critical Friction Threshold (CFT), Worst Itch Numeric Rating Scale (WI-NRS)"
            },
            {
              "key": "Geographic and Enrollment Details",
              "value": "Phase 2 study planned at approximately 85 sites across 12 countries; enrollment of around 180 patients in two cohorts (90 with cold urticaria and 90 with symptomatic dermographism)"
            },
            {
              "key": "Additional Development",
              "value": "Expansion into PN and EoE indications with future studies planned, including the use of subcutaneous formulation for PN"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 61,
          "title": "Barzolvolimab Development Activities and Bispecific Platform",
          "data": [
            {
              "key": "Subcutaneous Formulation",
              "value": "Manufacturing activities to support the clinical program for the barzolvolimab subcutaneous formulation have been completed. In September 2021, dosing was initiated in a randomized, double-blind, placebo-controlled Phase 1 study evaluating safety and pharmacokinetics."
            },
            {
              "key": "Phase 2 Clinical Studies",
              "value": "Phase 2 multi-dose studies in urticaria are designed to evaluate doses of 75 mg and 150 mg administered every 4 weeks and 300 mg every 8 weeks, supporting a 0.5 to 2 ml injection volume."
            },
            {
              "key": "Manufacturing Process Transfer",
              "value": "In 2022, the current barzolvolimab manufacturing process was transferred to a contract manufacturing organization to support late-stage trials and prepare for potential commercialization."
            },
            {
              "key": "Toxicology Study and Recovery",
              "value": "Interim data from a six-month chronic toxicology study in non-human primates (reported in February 2022) showed a profound impact on spermatogenesis due to KIT inhibition, with full recovery observed in all male animals during a recovery period that lasted approximately one year, as reported in December 2022."
            },
            {
              "key": "Bispecific Antibody Platform",
              "value": "Development of the next generation bispecific antibody platform is underway with candidates such as CDX-585 and CDX-527 for inflammatory diseases and oncology. CDX-585 combines PD-1 blockade with anti-ILT4 blockade, and CDX-527 couples PD-L1 blockade with CD27 co-stimulation. Both candidates have progressed through preclinical development with IND-enabling studies and are expected to enter clinical trials in 2023."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 62,
          "title": "Clinical Trials Program Update & Critical Accounting Policies",
          "data": [
            {
              "key": "Clinical Trials Status",
              "value": "Enrollment for the ovarian cancer expansion cohort did not meet internal timelines; enrollment was closed and the study program discontinued"
            },
            {
              "key": "CDX-1140 Program Details",
              "value": "CDX-1140, a fully human agonist monoclonal antibody targeting CD40, was evaluated in a Phase 1 study in patients with recurrent, locally advanced or metastatic solid tumors and B cell lymphomas. A maximum tolerated dose of 1.5 mg/kg was established with evidence of clinical activity both as a monotherapy and in combination with pembrolizumab. However, despite clinical benefit, broader questions about optimal clinical settings and regimens have led to a decision not to progress further with company-sponsored studies, with future exploration through third-party sponsored studies."
            },
            {
              "key": "Pipeline Prioritization",
              "value": "Due to pipeline priorities and resource requirements, further company-sponsored studies have been halted as of August 2022."
            },
            {
              "key": "Critical Accounting Policies",
              "value": "The document also discusses significant accounting policies, including contingent consideration from a prior acquisition, revenue recognition, and other estimates that require significant judgment in financial reporting."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 64,
          "title": "R&D and Stock-Based Compensation Expense Details",
          "data": [
            {
              "key": "IPR&D Impairment Assessment",
              "value": "Each IPR&D asset is assessed for impairment at least annually or when impairment indicators are present. The Company may assess qualitative factors to determine if impairment is likely, and if a quantitative test is necessary."
            },
            {
              "key": "Research and Development Expenses",
              "value": "R&D costs, including clinical trial expenses, manufacturing of clinical materials, toxicology, preclinical studies, personnel, depreciation, license fees, and funding of outside contracted research, are expensed as incurred. Costs from CRO and CMO services are accrued based on estimated costs, with adjustments made when actual expenses differ."
            },
            {
              "key": "Stock-Based Compensation Expense",
              "value": "Expense for stock-based awards to employees, consultants, and non-employee directors is recorded based on estimated fair values at the grant date and recognized using the straight-line method over the vesting period. Estimates include assumptions around historical volatility and expected term."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 68,
          "title": "Year-over-Year Expense Comparison (in thousands)",
          "data": [
            {
              "key": "Personnel Expenses",
              "value": "2021: 26,424; 2020: 21,896; Dollar Change: +4,528; Percent Change: +21%. Increase due to higher stock-based compensation and an increased employee headcount."
            },
            {
              "key": "Laboratory Supplies",
              "value": "2021: 5,981; 2020: 4,393; Dollar Change: +1,588; Percent Change: +36%. Increase driven by higher purchases of laboratory materials and supplies."
            },
            {
              "key": "Facility Expenses",
              "value": "2021: 4,771; 2020: 6,367; Dollar Change: -1,596; Percent Change: -25%. Decline primarily due to consolidation of the Massachusetts lab and manufacturing facilities and lower depreciation."
            },
            {
              "key": "Product Development Expenses",
              "value": "2021: 12,230; 2020: 6,233; Dollar Change: +5,997; Percent Change: +96%. Increase attributed to higher clinical trial and contract research expenses (e.g., barzolvolimab clinical trial)."
            },
            {
              "key": "Table Summary",
              "value": "The table provides a year-over-year comparison of R&D expenses across key categories, with notable increases in Personnel, Laboratory Supplies, and Product Development, and a decrease in Facility costs."
            },
            {
              "key": "Additional R&D-related Notes",
              "value": "Further discussion includes details on impairment assessments for IPR&D assets (TAM program and CDX-3379) and a gain on fair value remeasurement of contingent consideration, which reflect adjustments related to R&D investments and strategy."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 87,
          "title": "Leases and Intangible Assets Disclosure",
          "data": [
            {
              "key": "Operating Lease Expense 2022",
              "value": "$1.9 million"
            },
            {
              "key": "Operating Lease Expense 2021",
              "value": "$1.9 million"
            },
            {
              "key": "Operating Lease Expense 2020",
              "value": "$2.3 million"
            },
            {
              "key": "Variable Lease Expense 2022",
              "value": "$0.8 million"
            },
            {
              "key": "Variable Lease Expense 2021",
              "value": "$0.7 million"
            },
            {
              "key": "Variable Lease Expense 2020",
              "value": "$1.2 million"
            },
            {
              "key": "Cash Paid for Lease Liabilities 2022",
              "value": "$1.9 million"
            },
            {
              "key": "Cash Paid for Lease Liabilities 2021",
              "value": "$1.8 million"
            },
            {
              "key": "Cash Paid for Lease Liabilities 2020",
              "value": "$2.4 million"
            },
            {
              "key": "Weighted-Average Remaining Lease Term (2022)",
              "value": "2 years"
            },
            {
              "key": "Weighted-Average Discount Rate (2022)",
              "value": "10.0%"
            },
            {
              "key": "Future Minimum Lease Payments Total",
              "value": "$4,548M"
            },
            {
              "key": "Imputed Interest Deduction",
              "value": "-$515M"
            },
            {
              "key": "Present Value of Operating Lease Liabilities",
              "value": "$4,033M"
            },
            {
              "key": "Indefinite-Lived Intangible Assets Carrying Value",
              "value": "$27.2 million"
            },
            {
              "key": "IPR&D - Anti-KIT Program",
              "value": "Includes barzolvolimab in Phase 2 development; asset not impaired as of Q4 2022"
            },
            {
              "key": "TAM Program IPR&D Impairment Q4 2020",
              "value": "$14.5 million (partial impairment)"
            },
            {
              "key": "TAM Program IPR&D Impairment Q3 2021",
              "value": "$3.5 million (full impairment)"
            },
            {
              "key": "CDX-3379 IPR&D Impairment Q2 2020",
              "value": "$3.5 million (full impairment)"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_new_product_launches": {
      "value": true,
      "elements": [
        {
          "type": "product_launch",
          "page": 8,
          "title": "Clinical Trial Update: Phase 1b Study of Barzolvolimab in Inducible Urticarias",
          "data": [
            {
              "key": "Therapies Explored",
              "value": "Cold-induced urticaria, symptomatic dermographism (scratch-induced), and cholinergic (exercise-induced) urticaria"
            },
            {
              "key": "Study Phase",
              "value": "Phase 1b, open-label clinical trial"
            },
            {
              "key": "Dosage",
              "value": "Single dose of 3 mg/kg; additional cohort at 1.5 mg/kg in ColdU patients"
            },
            {
              "key": "Patient Population",
              "value": "Patients refractory to antihistamines with inducible urticarias"
            },
            {
              "key": "Enrollment & Cohorts",
              "value": "Enrollment opened in December 2020; added cohorts in March and June 2021"
            },
            {
              "key": "Key Clinical Endpoints",
              "value": "Safety assessment, improvements in provocation thresholds, Urticaria Control Test (UCT) and Dermatology Life Quality Index (DLQI) scores"
            },
            {
              "key": "Outcomes",
              "value": "95% complete response rate; rapid (within 1 week) and durable responses; marked decrease in disease impact on quality of life"
            },
            {
              "key": "Adverse Events",
              "value": "Hair color changes, infusion reactions, taste changes, nasopharyngitis, malaise, and headache; most events were mild and resolved over time"
            },
            {
              "key": "Pharmacodynamic Insights",
              "value": "Marked decreases in tryptase levels and skin mast cells, supporting a central role of mast cells in disease pathogenesis"
            },
            {
              "key": "Publication Reference",
              "value": "Data published in Allergy (Nov 2022, doi: 10.1111/all.15585)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 11,
          "title": "Table of Contents – Bispecific Platform and Pipeline Overview",
          "data": [
            {
              "key": "Platform Overview",
              "value": "Next generation bispecific antibody platform aimed at expanding the pipeline with additional candidates for inflammatory diseases and oncology. Targets are selected based on new science and compatibility with existing antibody programs."
            },
            {
              "key": "CDX-585",
              "value": "Combines proprietary PD-1 blockade and anti-ILT4 blockade to inhibit immunosuppressive signals in T cells and myeloid cells. Preclinical studies showed potent inhibition of PD-1 signaling, enhanced inflammatory responses in immune cells, and in vivo efficacy in a melanoma humanized mouse model. Completed GMP manufacturing and IND-enabling studies; expected to enter clinical trials in 2023 for solid tumors."
            },
            {
              "key": "CDX-527",
              "value": "Uses anti-PD-L1 and CD27 antibodies to couple CD27 co-stimulation with PD-L1/PD-1 blockade, aimed at priming and activating anti-tumor T cell responses. Phase 1 dose-escalation study was initiated but later discontinued after internal review and failure to meet enrollment timelines in the expansion cohort for ovarian cancer."
            },
            {
              "key": "CDX-1140",
              "value": "A fully human CD40 agonist monoclonal antibody targeting a key immune activator on dendritic cells, macrophages, and B cells. Phase 1 study conducted in patients with advanced solid tumors and B cell lymphomas, showing some clinical activity. However, due to unresolved questions regarding optimal use and resource prioritization, company-sponsored studies were halted."
            },
            {
              "key": "Partnerships",
              "value": "The company is open to co-development and commercialization partnerships to support its research and development programs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 59,
          "title": "Table of Contents – Clinical Study Outcomes for Barzolvolimab",
          "data": [
            {
              "key": "Study Population & Baseline",
              "value": "Patients in both treatment groups reported disease impact on QoL; 80% achieved minimal/none (DLQI score 0-1) after dosing."
            },
            {
              "key": "Biomarker Efficacy",
              "value": "A single dose of barzolvolimab led to marked decreases in tryptase levels and reduced skin mast cells, correlating with improvements in provocation testing and clinical activity."
            },
            {
              "key": "Adverse Events",
              "value": "Common events included hair color changes (76%), infusion reactions (43%), taste changes (38%), nasopharyngitis (24%), malaise (24%), and headache (19%). Most adverse events were mild and resolved over time."
            },
            {
              "key": "Long Term Follow-Up",
              "value": "Data from December 2022 at GA²LEN Global Urticaria Forum showed that while most patients experienced return of symptoms between weeks 12 and 36, some maintained control up to week 36."
            },
            {
              "key": "Dose Cohorts & Response",
              "value": "In the 1.5 mg/kg cohort, 100% of evaluable patients achieved complete response by provocation testing, with rapid onset (6 of 9 within 1 week) and a median duration of response of over 51 days."
            },
            {
              "key": "Pharmacodynamic Findings",
              "value": "Serum tryptase levels returned to pretreatment levels during follow-up while skin mast cells recovered more slowly; tissue KIT signaling was rapidly inhibited and reactivated around 18 weeks post-dose."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_capital_expenditures": {
      "value": true,
      "elements": [
        {
          "type": "capital_expenditure",
          "page": 81,
          "title": "Capitalization, Amortization, and Lease Accounting Policies",
          "data": [
            {
              "key": "Asset Capitalization",
              "value": "Expenditures for property, plant, and equipment are capitalized based on their nature and stage of construction. Costs incurred in project planning, design, construction, and installation are capitalized until the asset is substantially complete and ready for use."
            },
            {
              "key": "Maintenance vs. Improvements",
              "value": "Routine maintenance and repairs are expensed, while significant improvements that extend the asset's useful life are capitalized."
            },
            {
              "key": "Leases",
              "value": "Operating leases for offices, manufacturing, and laboratory spaces are recognized on the balance sheet as right-of-use assets and liabilities, based on the present value of future lease payments. Adjustments are made for prepaid/accrued amounts, initial direct costs, and incentives."
            },
            {
              "key": "Contingent Consideration",
              "value": "Contingent considerations from business combinations (e.g. acquisition of Kolltan) are recorded at fair value and revalued quarterly. Adjustments depend on factors such as clinical events, regulatory approvals, and discount rates."
            },
            {
              "key": "Intangible Assets (IPR&D)",
              "value": "IPR&D assets acquired in business combinations are recorded at fair value and capitalized until the underlying project is completed or impaired, after which they are amortized or written down as necessary."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_financial_performance_indicators": {
      "value": true,
      "elements": [
        {
          "type": "financial_performance",
          "page": 61,
          "title": "Year-over-Year Expense Comparison (December 31, 2021-2022)",
          "data": [
            {
              "key": "Personnel",
              "value": "Increased from 26424 to 32674 (Increase of 6250, 24%)"
            },
            {
              "key": "Laboratory supplies",
              "value": "Increased from 5981 to 6310 (Increase of 329, 6%)"
            },
            {
              "key": "Facility",
              "value": "Relatively unchanged: decreased from 4771 to 4764 (Decrease of 7, 0%)"
            },
            {
              "key": "Product development",
              "value": "Increased from 12230 to 32156 (Increase of 19926, 163%)"
            },
            {
              "key": "Expense Summary",
              "value": "Total R&D expenses rose significantly, primarily driven by product development and personnel costs."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 63,
          "title": "Revenue Recognition and Intangible Assets",
          "data": [
            {
              "key": "Revenue Recognition Policy",
              "value": "Revenues are recognized when performance obligations in contracts are satisfied. The Company uses a cost-to-cost measure (percentage-of-completion) to recognize revenue based on costs incurred relative to total estimated costs. Agreements include nonrefundable signing and licensing fees, research and development funding, milestone payments, and royalties."
            },
            {
              "key": "Contract Manufacturing and R&D Arrangements",
              "value": "Revenue from manufacturing and R&D arrangements is recognized on an output basis. Time-and-material contracts recognize revenue as labor hours and direct expenses are incurred, while fixed-price contracts recognize revenue as work progresses."
            },
            {
              "key": "Intangible and Long-Lived Assets",
              "value": "Long-lived assets are evaluated for impairment using undiscounted future cash flows. IPR&D assets acquired in business combinations are recorded at fair value, capitalized until project completion or impairment, at which point they are amortized or written down."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 65,
          "title": "Year Ended December 31, Financial Comparison",
          "data": [
            {
              "key": "Product development and licensing agreements",
              "value": "2022: 56, 2021: 31 (Increase of 25, 81%)"
            },
            {
              "key": "Contracts and grants",
              "value": "2022: 2301, 2021: 4620 (Decrease of 2319, -50%)"
            },
            {
              "key": "Total revenues",
              "value": "2022: 2357, 2021: 4651 (Decrease of 2294, -49%)"
            },
            {
              "key": "Research and development",
              "value": "2022: 82258, 2021: 53311 (Increase of 28947, 54%)"
            },
            {
              "key": "General and administrative",
              "value": "2022: 27195, 2021: 20488 (Increase of 6707, 33%)"
            },
            {
              "key": "Intangible asset impairment",
              "value": "2022: 0, 2021: 3500 (Decrease of 3500, -100%)"
            },
            {
              "key": "Gain on fair value remeasurement of contingent consideration",
              "value": "2022: -6862, 2021: -1405 (Increase of 5457, 388%)"
            },
            {
              "key": "Litigation settlement related loss",
              "value": "2022: 15000, 2021: 0 (New expense of 15000)"
            },
            {
              "key": "Total operating expenses",
              "value": "2022: 117591, 2021: 75894 (Increase of 41697, 55%)"
            },
            {
              "key": "Operating loss",
              "value": "2022: -115234, 2021: -71243 (Increase of 43991, 62%)"
            },
            {
              "key": "Investment and other income, net",
              "value": "2022: 2909, 2021: 505 (Increase of 2404, 476%)"
            },
            {
              "key": "Net loss before income tax benefit",
              "value": "2022: -112325, 2021: -70738 (Increase of 41587, 59%)"
            },
            {
              "key": "Net loss",
              "value": "2022: -112325, 2021: -70511 (Increase of 41814, 59%)"
            },
            {
              "key": "Commentary - Net Loss",
              "value": "The $41.8 million increase in net loss was primarily due to a $15.0 million litigation settlement loss in Q2 2022, along with higher R&D and general & administrative expenses, partially offset by an increase in the gain on fair value remeasurement of contingent consideration."
            },
            {
              "key": "Commentary - Revenue",
              "value": "Product development and licensing agreements revenue remained relatively consistent; however, contracts and grants revenue decreased by $2.3 million due to lower service revenues under specific agreements, with expectations of future recovery."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 66,
          "title": "Expense Analysis and Forecast",
          "data": [
            {
              "key": "Personnel Expenses",
              "value": "Increased by $6.3 million for year ended December 31, 2022 vs 2021 due to higher stock-based compensation expense and increased employee headcount. Forecast: expected to increase further with added headcount for barzolvolimab development."
            },
            {
              "key": "Laboratory Supplies Expenses",
              "value": "Increased by $0.3 million primarily due to higher laboratory services, materials and supplies purchases. Forecast: expected to remain relatively consistent with possible quarterly fluctuations."
            },
            {
              "key": "Facility Expenses",
              "value": "Expenses for depreciation, amortization, utilities, rent, and maintenance remained relatively consistent year-over-year. Forecast: expected to remain roughly consistent with potential quarterly fluctuations."
            },
            {
              "key": "Product Development Expenses",
              "value": "Increased by $19.9 million due to higher barzolvolimab clinical trial and contract manufacturing expenses. Forecast: expected further increase as clinical trial and manufacturing expenses rise."
            },
            {
              "key": "General and Administrative Expenses",
              "value": "Increased by $6.7 million, driven by higher stock-based compensation, legal costs, and commercial planning expenses for barzolvolimab. Forecast: expected to remain relatively consistent with possible quarterly fluctuations."
            },
            {
              "key": "Intangible Asset Impairment",
              "value": "A non-cash impairment charge of $3.5 million was recorded in Q3 2021 for the TAM program IPR&D asset due to lack of third-party interest."
            },
            {
              "key": "Gain on Fair Value Remeasurement of Contingent Consideration",
              "value": "Recorded a gain of $6.9 million for the year ended December 31, 2022, primarily due to the decision to deprioritize the CDX-1140 program."
            },
            {
              "key": "Litigation Settlement Related Loss",
              "value": "A loss of $15.0 million was recorded in Q2 2022 related to the Initial Payment under the binding settlement term sheet with SRS."
            },
            {
              "key": "Investment and Other Income, Net",
              "value": "Increased by $2.4 million for year ended December 31, 2022, primarily due to higher interest rates on fixed income investments and income from sale of New Jersey tax benefits. Forecast: expected to increase with further higher interest rates."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 67,
          "title": "Financial Performance Comparison 2021 vs 2020 and Discussion on Net Loss & Revenue",
          "data": [
            {
              "key": "Income Tax Benefit",
              "value": "$0.2 million non-cash income tax benefit recorded for the impairment of the TAM program IPR&D asset in Q3 2021."
            },
            {
              "key": "Product development and licensing agreements",
              "value": "2021: 31, 2020: 2301, Change: -2270 (-99%)"
            },
            {
              "key": "Contracts and grants",
              "value": "2021: 4620, 2020: 5117, Change: -497 (-10%)"
            },
            {
              "key": "Total revenues",
              "value": "2021: 4651, 2020: 7418, Change: -2767 (-37%)"
            },
            {
              "key": "Research and development",
              "value": "2021: 53311, 2020: 42534, Change: +10777 (+259%)"
            },
            {
              "key": "General and administrative",
              "value": "2021: 20488, 2020: 14456, Change: +6032 (+42%)"
            },
            {
              "key": "Intangible asset impairment",
              "value": "2021: 3500, 2020: 18000, Change: -14500 (-81%)"
            },
            {
              "key": "Gain on fair value remeasurement of contingent consideration",
              "value": "2021: -1405, 2020: -4218, Change: -2813 (-67%)"
            },
            {
              "key": "Total operating expenses",
              "value": "2021: 75894, 2020: 70772, Change: +5122 (+7%)"
            },
            {
              "key": "Operating loss",
              "value": "2021: -71243, 2020: -63354, Change: +7889 (+12%)"
            },
            {
              "key": "Investment and other income, net",
              "value": "2021: 505, 2020: 2407, Change: -1902 (-79%)"
            },
            {
              "key": "Net loss before income tax benefit",
              "value": "2021: -70738, 2020: -60947, Change: +9791 (+16%)"
            },
            {
              "key": "Income tax benefit (Table)",
              "value": "2021: 227, 2020: 1167, Change: -940 (-81%)"
            },
            {
              "key": "Net loss",
              "value": "2021: -70511, 2020: -59780, Change: +10731 (+18%)"
            },
            {
              "key": "Net Loss Increase Observation",
              "value": "$10.7 million increase in net loss for 2021 primarily due to higher R&D and general & administrative expenses, a decrease in the gain on fair value remeasurement of contingent consideration, and lower non-cash intangible asset impairment expense."
            },
            {
              "key": "Revenue Details",
              "value": "The Rockefeller Agreement and related transactions impacted revenue: a $2.3 million decrease in product development and licensing agreements driven by a one-off $1.8 million receipt in Q1 2020, and a $0.5 million decrease in contracts and grants due to reduced services under existing agreements."
            },
            {
              "key": "Summary",
              "value": "Key observations: Total revenues decreased by 37%, operating expenses increased by 7% (largely due to increased R&D costs), and net loss increased by 18% in 2021 compared to 2020. Significant changes include a steep decline in product development revenues and intangible asset impairment, with a substantial rise in research and development expenses."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 69,
          "title": "Financial Performance and Liquidity",
          "data": [
            {
              "key": "Investment and Other Income, Net Decrease",
              "value": "$1.9 million decrease for the year ended December 31, 2021 compared to 2020, primarily due to lower other income from sale of New Jersey tax benefits"
            },
            {
              "key": "Income Tax Benefit",
              "value": "$0.2 million non-cash income tax benefit recorded for the year ended December 31, 2021, related to impairment of the TAM program IPR&D asset in Q3 2021"
            },
            {
              "key": "Cash Equivalents and Liquidity",
              "value": "As of December 31, 2022, cash, cash equivalents and marketable securities amounted to $305.0 million; investments held in short-term, highly liquid assets"
            },
            {
              "key": "Loss and Operational Cash Flow",
              "value": "Recurring losses with a reported loss of $112.3 million for the year ended December 31, 2022 and net cash used in operations of $103.7 million"
            },
            {
              "key": "Future Capital and Funding",
              "value": "Plans to fund operations through 2025 with ongoing and planned clinical trials; potential need for additional financing via licensing, business combinations, debt issuance, or equity financing"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 70,
          "title": "Cash Flow Activities and Equity Offerings Overview",
          "data": [
            {
              "key": "Operating Activities (2022)",
              "value": "Net cash used of $103.7 million for the year ended December 31, 2022; increased primarily due to higher R&D and general/admin expenses and a $15.0 million initial payment under the Settlement Agreement."
            },
            {
              "key": "Operating Activities (2021)",
              "value": "Net cash used of $60.9 million for the year ended December 31, 2021; increase from $40.4 million in 2020 due to higher expenses and a decrease in revenue."
            },
            {
              "key": "Investing Activities (2022)",
              "value": "Net cash provided of $89.9 million for the year ended December 31, 2022, driven by net sales and maturities of marketable securities."
            },
            {
              "key": "Investing Activities (2021)",
              "value": "Net cash used of $216.2 million for the year ended December 31, 2021, primarily due to net purchases of marketable securities; compared to $98.2 million used in 2020."
            },
            {
              "key": "Financing Activities (2022)",
              "value": "Net cash provided of $4.1 million for the year ended December 31, 2022, largely reflecting a decline in net proceeds from stock issuances."
            },
            {
              "key": "Financing Activities (2021)",
              "value": "Net cash provided of $272.4 million for the year ended December 31, 2021, compared to $171.2 million in 2020, due to increased net proceeds from stock issuances."
            },
            {
              "key": "Equity Offerings",
              "value": "In November 2020, filed a shelf registration; issued 7,125,004 shares through Cantor in 2020 generating net proceeds of $29.4 million. No shares were sold in 2021 and 2022. At December 31, 2022, $50.0 million remained available under the prospectus supplement."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 72,
          "title": "Report of Independent Registered Public Accounting Firm",
          "data": [
            {
              "key": "Company",
              "value": "Celldex Therapeutics, Inc."
            },
            {
              "key": "Financial Statement Dates",
              "value": "December 31, 2022 and December 31, 2021"
            },
            {
              "key": "Reporting Period",
              "value": "Three years ended December 31, 2022"
            },
            {
              "key": "Audit Opinion Summary",
              "value": "The consolidated financial statements present fairly, in all material respects, the financial position of the Company, its operations results, and cash flows."
            },
            {
              "key": "Internal Control Opinion",
              "value": "Effective internal control over financial reporting was maintained as of December 31, 2022."
            },
            {
              "key": "Audit Standards",
              "value": "Conducted in accordance with PCAOB standards and based on the COSO Internal Control - Integrated Framework (2013)"
            },
            {
              "key": "Basis for Opinion",
              "value": "Audits involved risk assessment, testing of balances and controls, and evaluation of accounting principles and estimates."
            },
            {
              "key": "Audit Firm Status",
              "value": "Independent Registered Public Accounting Firm registered with PCAOB"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 74,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Audit Procedures",
              "value": "Performed procedures and evaluated audit evidence related to the consolidated financial statements. Procedures included testing controls on management's determination of the accounting treatment for future milestone payments, reviewing the Settlement Agreement, and assessing proper disclosure in accordance with relevant standards."
            },
            {
              "key": "Auditor",
              "value": "PricewaterhouseCoopers LLP"
            },
            {
              "key": "Location",
              "value": "Boston, Massachusetts"
            },
            {
              "key": "Report Date",
              "value": "February 28, 2023"
            },
            {
              "key": "Audit Relationship",
              "value": "Served as the Company's auditor since 2008"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 75,
          "title": "CELLDEX THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS",
          "data": [
            {
              "key": "Statement Title",
              "value": "Balance Sheet Assets and Liabilities"
            },
            {
              "key": "Presentation",
              "value": "Amounts in thousands, except share and per share amounts"
            },
            {
              "key": "Categories",
              "value": "Current assets, Non-current assets, Liabilities, Stockholders' equity"
            },
            {
              "key": "Highlights",
              "value": "Total assets $352,735 (down from $444,654); Marketable securities largest current asset at $275,523; Strong equity position at $326,204 (down from $419,476); Total liabilities at $26,531; Substantial accumulated deficit of $1,255,932 indicating historical losses"
            },
            {
              "key": "Accompanying Notes",
              "value": "The accompanying notes are an integral part of the financial statements. 71 (1,143,607)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 76,
          "title": "Financial Statement Summary",
          "data": [
            {
              "key": "Revenues (2022)",
              "value": "2357"
            },
            {
              "key": "Revenues (2021)",
              "value": "4651"
            },
            {
              "key": "Revenues (2020)",
              "value": "7418"
            },
            {
              "key": "Operating expenses (2022)",
              "value": "117591"
            },
            {
              "key": "Operating expenses (2021)",
              "value": "75894"
            },
            {
              "key": "Operating expenses (2020)",
              "value": "70772"
            },
            {
              "key": "Operating loss (2022)",
              "value": "-115234"
            },
            {
              "key": "Operating loss (2021)",
              "value": "-71243"
            },
            {
              "key": "Operating loss (2020)",
              "value": "-63354"
            },
            {
              "key": "Net loss (2022)",
              "value": "-112325"
            },
            {
              "key": "Net loss (2021)",
              "value": "-70511"
            },
            {
              "key": "Net loss (2020)",
              "value": "-59780"
            },
            {
              "key": "Basic and diluted net loss per common share (2022)",
              "value": "-2.40"
            },
            {
              "key": "Basic and diluted net loss per common share (2021)",
              "value": "-1.64"
            },
            {
              "key": "Basic and diluted net loss per common share (2020)",
              "value": "-2.02"
            },
            {
              "key": "Summary",
              "value": "Declining revenues and increasing losses from 2020 to 2022. Revenues decreased significantly from $7.4M (2020) to $2.4M (2022), operating expenses increased from $70.8M (2020) to $117.6M (2022), and net loss deteriorated from $59.8M (2020) to $112.3M (2022). Notable items include a litigation settlement loss of $15M in the most recent year and intangible asset impairments in previous years."
            },
            {
              "key": "Additional Financial Metrics",
              "value": "Metrics noted: Revenues: Contracts and grants, Total revenues, Operating loss, Income tax benefit, Net loss, Comprehensive loss. Figures provided: 72, (4,218), (63,354), (60,947), (59,780), (2.02), (59,780), (30), (59,810)."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 78,
          "title": "Cash Flow Statement",
          "data": [
            {
              "key": "Net Loss",
              "value": "2022: -112325, 2021: -70511, 2020: -59780"
            },
            {
              "key": "Net cash used in operating activities",
              "value": "2022: -103732, 2021: -60909, 2020: -40404"
            },
            {
              "key": "Net cash provided by (used in) investing activities",
              "value": "2022: 89942, 2021: -216156, 2020: -98218"
            },
            {
              "key": "Net cash provided by financing activities",
              "value": "2022: 4076, 2021: 272372, 2020: 171226"
            },
            {
              "key": "Cash and cash equivalents at end of period",
              "value": "2022: 29429, 2021: 39143, 2020: 43836"
            },
            {
              "key": "Summary",
              "value": "The table presents a cash flow statement for 2020-2022. It shows increasing net losses, deteriorating operating cash flows, a significant decline in financing activities in 2022 compared to previous years, and an overall decline in cash reserves from 2020 to 2022."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 79,
          "title": "CELLDEX THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS",
          "data": [
            {
              "key": "Business Overview",
              "value": "Celldex Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies, primarily barzolvolimab (CDX-0159) and CDX-585."
            },
            {
              "key": "Cash and Marketable Securities (Dec 31, 2022)",
              "value": "$305.0 million"
            },
            {
              "key": "Net Loss (Year Ended Dec 31, 2022)",
              "value": "$112.3 million"
            },
            {
              "key": "Net Cash Used in Operations (2022)",
              "value": "$103.7 million"
            },
            {
              "key": "Liquidity and Funding Strategy",
              "value": "The Company believes its cash resources are sufficient for at least the next 12 months; however, additional capital may be raised via licensing deals, business combinations, debt issuance, or equity offerings if needed."
            },
            {
              "key": "Risk Factors Related to Capital",
              "value": "Financing risks include potential dilution from equity financings, constraints from debt financing, and reliance on milestone payments under a Settlement Agreement."
            },
            {
              "key": "Accounting Policies Summary",
              "value": "The financial statements are consolidated and prepared in accordance with U.S. GAAP, with operations presented in one segment covering development, manufacturing, and commercialization of therapeutics."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 80,
          "title": "Financial Disclosure – Cash, Securities, and Risk Management",
          "data": [
            {
              "key": "Cash and Cash Equivalents",
              "value": "The Company considers all highly liquid investments purchased with a maturity date of 90 days or less at the date of purchase to be cash equivalents. These primarily consist of money market funds and debt securities."
            },
            {
              "key": "Marketable Securities",
              "value": "Excess cash is invested in marketable securities including municipal bond securities, U.S. government agency securities, and highly rated corporate bonds. These are classified as current assets and stated at fair value with unrealized gains and losses included in accumulated other comprehensive income (loss) until realized."
            },
            {
              "key": "Concentration of Credit Risk and Significant Customers and Suppliers",
              "value": "Discussion on financial instruments exposed to credit risk, primarily cash, cash equivalents, marketable securities, and accounts receivable. The Company invests in secure debt instruments and relies on major customers, with revenue from Rockefeller University comprising 75% of total revenue in 2022, and similar concentration disclosures for prior years."
            },
            {
              "key": "Fair Value Measurements",
              "value": "Assets and liabilities are measured at fair value using a three-level hierarchy under U.S. GAAP. Level 1 inputs include quoted prices in active markets; Level 2 inputs use quoted prices for similar assets; and Level 3 involves unobservable inputs based on management's assumptions."
            },
            {
              "key": "Property and Equipment",
              "value": "Property and equipment are stated at cost and depreciated over their estimated useful lives. Specific depreciation periods include five years for laboratory and office equipment, three years for computer equipment, and seven to ten years for manufacturing equipment. Leasehold improvements are also noted."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 82,
          "title": "Revenue Recognition and Impairment Policies",
          "data": [
            {
              "key": "Impairment Assessment",
              "value": "Each IPR&D asset is assessed for impairment at least annually or when impairment indicators are present. Long-lived assets, including intangible assets, are evaluated using undiscounted future cash flows to determine recoverability."
            },
            {
              "key": "Impairment of Long-Lived Assets",
              "value": "If future cash flows are not sufficient to recover the carrying amounts, assets are written down to their estimated fair values."
            },
            {
              "key": "Revenue Recognition Process",
              "value": "Revenues are recognized when performance obligations are satisfied. The process includes identifying the contract, determining performance obligations, estimating the transaction price, allocating the price to each obligation, and recognizing revenue as obligations are fulfilled."
            },
            {
              "key": "Revenue Sources",
              "value": "Revenue is derived from product development agreements with collaborators (including nonrefundable fees, milestone payments, royalties) as well as manufacturing and R&D arrangements. Recognition methods vary depending on the contract type (cost-to-cost measure for product development, output basis for time-and-material or fixed-price contracts)."
            },
            {
              "key": "Estimation Complexity",
              "value": "Estimations such as cost at completion are complex and subject to many variables including expected clinical trial costs, requiring significant judgment and periodic revisions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 83,
          "title": "Financial Statement Disclosures – Contract Assets, R&D, Patent Costs, Stock-Based Compensation, Foreign Currency Translation, and Income Taxes",
          "data": [
            {
              "key": "Contract Assets and Liabilities",
              "value": "Describes the classification of receivables versus contract assets; contract liabilities are recognized as deferred revenue on the balance sheet when payment is received in advance of performance."
            },
            {
              "key": "Research and Development Expenses",
              "value": "Expenses incurred for research and development include clinical trial costs, manufacturing clinical materials, toxicology, preclinical studies, personnel costs, depreciation, license fees, and funding for external contracted research (CRO and CMO services); costs are expensed as incurred with adjustments for timing differences."
            },
            {
              "key": "Patent Costs",
              "value": "Patent costs are expensed to general and administrative expense as incurred, with certain reimbursed costs recorded as revenues under product development and licensing agreements."
            },
            {
              "key": "Stock-Based Compensation",
              "value": "Stock-based awards to employees, consultants, and non-employee directors are expensed based on estimated fair values and recognized using the straight-line method over the vesting period, with adjustments for forfeitures."
            },
            {
              "key": "Foreign Currency Translation",
              "value": "Net unrealized gains and losses from foreign currency translation are included in accumulated other comprehensive income; a net unrealized gain of $2.6 million was recorded as of December 31, 2022 and 2021."
            },
            {
              "key": "Income Taxes",
              "value": "The Company applies the asset and liability method for income taxes, recognizes deferred tax assets and liabilities, reviews deferred tax assets quarterly for recoverability, and records uncertain tax positions with interest and penalties where applicable."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 84,
          "title": "Comprehensive Loss and Income Statement Details",
          "data": [
            {
              "key": "Comprehensive Loss",
              "value": "Comprised of net loss and certain changes in stockholders’ equity, including foreign currency translation adjustments and unrealized gains and losses on marketable securities."
            },
            {
              "key": "Net Loss Per Share",
              "value": "Basic net loss per common share and diluted net loss per common share are calculated using the weighted-average number of common shares outstanding, with no difference in periods of net loss."
            },
            {
              "key": "Table Data",
              "value": "The 'Comprehensive Income/Loss Statement' table shows changes in components such as marketable securities and foreign currency items between December 31, 2021 and December 31, 2022. Marketable securities deteriorated from -702 to -1336, while foreign currency remained stable at 2596, leading to a decrease in total comprehensive income from 1894 to 1260 (in thousands)."
            },
            {
              "key": "Recent Accounting Pronouncements",
              "value": "Discussion includes FASB guidance on Measurement of Credit Losses on Financial Instruments, effective January 1, 2023, which requires an expected losses model and additional disclosures related to credit risks."
            },
            {
              "key": "Accumulated Other Comprehensive Income",
              "value": "No amounts were reclassified; the section summarizes changes in accumulated other comprehensive income as a component of stockholders’ equity for the year ended December 31, 2022."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 91,
          "title": "Income Tax Benefit (Provision) Statement",
          "data": [
            {
              "key": "Income tax benefit (provision):",
              "value": ""
            },
            {
              "key": "Federal",
              "value": "17484"
            },
            {
              "key": "State",
              "value": "9606"
            },
            {
              "key": "Expiration of NOLs and R&D credit",
              "value": "-16862"
            },
            {
              "key": "Subtotal",
              "value": "10228"
            },
            {
              "key": "Deferred tax valuation allowance",
              "value": "-10228"
            },
            {
              "key": "Net Total",
              "value": "0"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 91,
          "title": "Income Tax Reconciliation Statement",
          "data": [
            {
              "key": "Pre-tax loss",
              "value": "-112325"
            },
            {
              "key": "Loss at statutory rates",
              "value": "-23588"
            },
            {
              "key": "Research and development credits",
              "value": "-3876"
            },
            {
              "key": "State taxes",
              "value": "-9606"
            },
            {
              "key": "Other",
              "value": "11421"
            },
            {
              "key": "Change in fair value remeasurement of contingent consideration",
              "value": "-1441"
            },
            {
              "key": "Expiration of NOLs and R&D credit",
              "value": "16862"
            },
            {
              "key": "Change in valuation allowance",
              "value": "10228"
            },
            {
              "key": "Income tax (benefit) provision",
              "value": "0"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 92,
          "title": "Deferred Tax Assets and Liabilities",
          "data": [
            {
              "key": "Table Title",
              "value": "Deferred Tax Assets and Liabilities"
            },
            {
              "key": "Concept",
              "value": "Deferred tax assets and liabilities are recognized based on temporary differences between financial reporting and tax basis of assets and liabilities using future expected enacted rates."
            },
            {
              "key": "Net operating loss carryforwards 2022",
              "value": "188255 (in thousands)"
            },
            {
              "key": "Net operating loss carryforwards 2021",
              "value": "183711 (in thousands)"
            },
            {
              "key": "Tax credit carryforwards 2022",
              "value": "50688 (in thousands)"
            },
            {
              "key": "Tax credit carryforwards 2021",
              "value": "47927 (in thousands)"
            },
            {
              "key": "Deferred research and development expenses 2022",
              "value": "67494 (in thousands)"
            },
            {
              "key": "Deferred research and development expenses 2021",
              "value": "59753 (in thousands)"
            },
            {
              "key": "Stock-based compensation 2022",
              "value": "9993 (in thousands)"
            },
            {
              "key": "Stock-based compensation 2021",
              "value": "14719 (in thousands)"
            },
            {
              "key": "Fixed assets 2022",
              "value": "1193 (in thousands)"
            },
            {
              "key": "Fixed assets 2021",
              "value": "1287 (in thousands)"
            },
            {
              "key": "Accrued expenses and other 2022",
              "value": "373 (in thousands)"
            },
            {
              "key": "Accrued expenses and other 2021",
              "value": "370 (in thousands)"
            },
            {
              "key": "Subtotal 2022",
              "value": "317996 (in thousands)"
            },
            {
              "key": "Subtotal 2021",
              "value": "307767 (in thousands)"
            },
            {
              "key": "IPR&D intangibles",
              "value": "-6840 (in thousands)"
            },
            {
              "key": "Total deferred tax assets and liabilities 2022",
              "value": "311156 (in thousands)"
            },
            {
              "key": "Total deferred tax assets and liabilities 2021",
              "value": "300927 (in thousands)"
            },
            {
              "key": "Valuation allowance 2022",
              "value": "-312769 (in thousands)"
            },
            {
              "key": "Valuation allowance 2021",
              "value": "-302540 (in thousands)"
            },
            {
              "key": "Net deferred tax liability",
              "value": "Effectively zero due to full valuation allowance despite reported numbers"
            },
            {
              "key": "Additional Narrative",
              "value": "The Company has maintained a full valuation allowance against its deferred tax assets. Additional discussion covers the CARES Act provisions, impact of past net operating losses, R&D credit carryforwards, and limitations under Section 382 due to potential ownership changes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 95,
          "title": "Evaluation of Disclosure Controls and Internal Control over Financial Reporting",
          "data": [
            {
              "key": "Disclosure Controls Evaluation Date",
              "value": "December 31, 2022"
            },
            {
              "key": "Management Involved",
              "value": "Chief Executive Officer and Chief Financial Officer"
            },
            {
              "key": "Disclosure Controls Conclusion",
              "value": "Effective at a reasonable assurance level"
            },
            {
              "key": "Internal Control Framework",
              "value": "Internal Control — Integrated Framework (2013) by COSO"
            },
            {
              "key": "Financial Reporting Reliability",
              "value": "Internal control over financial reporting deemed effective as of December 31, 2022"
            },
            {
              "key": "External Audit",
              "value": "PricewaterhouseCoopers LLP audited the internal control over financial reporting"
            },
            {
              "key": "SEC Regulatory Context",
              "value": "Evaluated under Rules 13a-15(e), 15d-15(e), 13a-15(f) and 15d-15(f) of the Exchange Act"
            },
            {
              "key": "Limitation Acknowledgment",
              "value": "Internal control over financial reporting may not prevent or detect all misstatements due to inherent limitations"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 107,
          "title": "CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM",
          "data": [
            {
              "key": "Company",
              "value": "Celldex Therapeutics, Inc."
            },
            {
              "key": "Purpose",
              "value": "Consent to incorporate the auditor's report in the Registration Statements on Form S-8 and Form S-3"
            },
            {
              "key": "Registration Statement Numbers",
              "value": "Form S-8: 333-257137, 333-239463, 333-232253, 333-232255, 333-219867, 333-219869, 333-205694, 333-189336, 333-182142, 333-151728, 333-117602; Form S-3: 333-249917, 333-239199, 333-235399, 333-215747"
            },
            {
              "key": "Report Date",
              "value": "February 28, 2023"
            },
            {
              "key": "Report Content",
              "value": "Audit report relating to the financial statements and the effectiveness of internal control over financial reporting"
            },
            {
              "key": "Auditor",
              "value": "PricewaterhouseCoopers LLP"
            },
            {
              "key": "Auditor Location",
              "value": "Boston, Massachusetts"
            },
            {
              "key": "Exhibit",
              "value": "Exhibit 23.1"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 108,
          "title": "Exhibit 31.1 CERTIFICATION",
          "data": [
            {
              "key": "Certified By",
              "value": "Anthony S. Marucci"
            },
            {
              "key": "Title",
              "value": "President and Chief Executive Officer"
            },
            {
              "key": "Date",
              "value": "February 28, 2023"
            },
            {
              "key": "Company",
              "value": "Celldex Therapeutics, Inc."
            },
            {
              "key": "Report Type",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "Certification Content",
              "value": "Certification attesting that the annual report's financial statements and disclosure controls fairly present the financial condition, results of operations, and cash flows, and that internal control over financial reporting has been evaluated."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 109,
          "title": "Certification Statement - Annual Report on Form 10-K",
          "data": [
            {
              "key": "Report",
              "value": "Annual Report on Form 10-K of Celldex Therapeutics, Inc."
            },
            {
              "key": "Certification Summary",
              "value": "The certifier, Sam Martin, attests that he has reviewed the annual report, and based on his knowledge the report contains no untrue statement or material omission. The financial statements and related financial information fairly present the financial condition, results of operations, and cash flows of the registrant."
            },
            {
              "key": "Internal Control Disclosure",
              "value": "The document explains that the registrant's disclosure controls, procedures, and internal control over financial reporting have been designed, supervised, evaluated, and any deficiencies or changes have been disclosed."
            },
            {
              "key": "Name",
              "value": "Sam Martin"
            },
            {
              "key": "Title",
              "value": "Senior Vice President and Chief Financial Officer"
            },
            {
              "key": "Date",
              "value": "February 28, 2023"
            },
            {
              "key": "Exhibit",
              "value": "Exhibit 31.2"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 110,
          "title": "CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350",
          "data": [
            {
              "key": "Company",
              "value": "Celldex Therapeutics, Inc."
            },
            {
              "key": "Report",
              "value": "Annual Report on Form 10-K for the period ended December 31, 2022"
            },
            {
              "key": "Certification Requirement",
              "value": "Compliance with 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002"
            },
            {
              "key": "Purpose",
              "value": "Certification that the Form 10-K fully complies with the Securities Exchange Act requirements and fairly presents the financial condition and results of operations of the Company"
            },
            {
              "key": "Certification Date",
              "value": "February 28, 2023"
            },
            {
              "key": "Executive 1",
              "value": "Anthony S. Marucci – President and Chief Executive Officer"
            },
            {
              "key": "Executive 2",
              "value": "Sam Martin – Senior Vice President and Chief Financial Officer"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_dividend_policy_changes": {
      "value": true,
      "elements": [
        {
          "type": "dividend_policy",
          "page": 53,
          "title": "MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES",
          "data": [
            {
              "key": "Trading Venue",
              "value": "Nasdaq Capital Market"
            },
            {
              "key": "Stock Symbol",
              "value": "CLDX"
            },
            {
              "key": "Shareholders of Record (Feb 13, 2023)",
              "value": "154"
            },
            {
              "key": "Closing Price (Feb 13, 2023)",
              "value": "$42.17 per share"
            },
            {
              "key": "Dividend Policy",
              "value": "No dividends have been paid since inception and none are planned for the foreseeable future."
            },
            {
              "key": "Performance Comparison - Chart Title",
              "value": "Stock Performance Comparison"
            },
            {
              "key": "Chart Description",
              "value": "Comparative performance of Celldex Therapeutics, Inc. stock versus Nasdaq US Benchmark TR Index and Nasdaq Pharmaceutical (Subsector) Index from 2017 to 2022. The chart assumes a $100 investment at baseline with dividend reinvestment."
            },
            {
              "key": "Performance Comparison - Table Summary",
              "value": "The table provides a comparative analysis of Celldex Therapeutics against market benchmarks over multiple periods. Celldex shows volatile performance compared to steadily growing indices."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_share_buyback_plans": {
      "value": false,
      "elements": []
    },
    "has_capital_structure_changes": {
      "value": true,
      "elements": [
        {
          "type": "capital_structure",
          "page": 1,
          "title": "Form 10-K Cover Page and Stock Information",
          "data": [
            {
              "key": "Form Type",
              "value": "10-K Annual Report"
            },
            {
              "key": "Fiscal Year End",
              "value": "December 31, 2022"
            },
            {
              "key": "Commission File Number",
              "value": "000-15006"
            },
            {
              "key": "Company Name",
              "value": "CELLDEX THERAPEUTICS, INC."
            },
            {
              "key": "Jurisdiction of Incorporation",
              "value": "Delaware"
            },
            {
              "key": "IRS Employer Identification Number",
              "value": "13-3191702"
            },
            {
              "key": "Principal Executive Offices",
              "value": "Perryville III Building, 53 Frontage Road, Suite 220, Hampton, New Jersey 08827"
            },
            {
              "key": "Telephone",
              "value": "(908) 200-7500"
            },
            {
              "key": "Security Listing Information",
              "value": "Common Stock, par value $.001, listed on NASDAQ Capital Market"
            },
            {
              "key": "Aggregate Market Value (June 30, 2022)",
              "value": "$1.3 billion"
            },
            {
              "key": "Shares Outstanding (February 13, 2023)",
              "value": "47,207,189 shares"
            },
            {
              "key": "Auditor",
              "value": "PricewaterhouseCoopers LLP, Boston, Massachusetts"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 13,
          "title": "Manufacturing, Capital Resources, and Dilution Risk",
          "data": [
            {
              "key": "Capital Requirements",
              "value": "Substantial capital resources are needed to complete development of drug candidates, obtain regulatory approvals, manufacture, and market products."
            },
            {
              "key": "Dilution of Existing Stockholders",
              "value": "Anticipation to raise funds by selling additional capital stock, which would dilute existing stockholders."
            },
            {
              "key": "Funding Sources",
              "value": "Potential sources include additional capital stock sales, research grants, commercial collaborations, and borrowing at high interest rates."
            },
            {
              "key": "Manufacturing Challenges",
              "value": "Reliance on Contract Manufacturing Organizations (CMOs) for large scale production, adherence to cGMP, and potential difficulties in scaling up manufacturing processes."
            },
            {
              "key": "Operational Considerations",
              "value": "Establishment of in-house manufacturing is capital intensive and requires significant modifications, hiring additional personnel, and meeting strict regulatory standards."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 71,
          "title": "Capital Raising and Market Risk Disclosures",
          "data": [
            {
              "key": "Q2 2020 Public Offering",
              "value": "Issued 15,384,614 shares of common stock in an underwritten public offering resulting in net proceeds of $141.4 million after fees and expenses."
            },
            {
              "key": "Q3 2021 Public Offering",
              "value": "Issued 6,845,238 shares of common stock in an underwritten public offering resulting in net proceeds of $269.9 million after fees and expenses."
            },
            {
              "key": "Market Risk Disclosures",
              "value": "The company discusses its investment portfolio comprised of financial instruments sensitive to market risk, used to preserve capital for funding operations including R&D. Investments are primarily in money market mutual funds and other marketable securities with minimal material exposure."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 77,
          "title": "Stockholders' Equity Statement 2019-2022",
          "data": [
            {
              "key": "Balance at December 31, 2019",
              "value": "shares: 16972077; par_value: 17; paid_in_capital: 41104706; comprehensive_income: 2619; accumulated_deficit: -1013316; total_equity: 94026"
            },
            {
              "key": "Balance at December 31, 2020",
              "value": "shares: 39603771; par_value: 40; paid_in_capital: 1279824; comprehensive_income: 2589; accumulated_deficit: -1073096; total_equity: 209357"
            },
            {
              "key": "Balance at December 31, 2021",
              "value": "shares: 46730198; par_value: 47; paid_in_capital: 1561142; comprehensive_income: 1894; accumulated_deficit: -1143607; total_equity: 419476"
            },
            {
              "key": "Balance at December 31, 2022",
              "value": "shares: 47200695; par_value: 47; paid_in_capital: 1580829; comprehensive_income: 1260; accumulated_deficit: -1255932; total_equity: 326204"
            },
            {
              "key": "Summary",
              "value": "This table shows the stockholders' equity statement from 2019 to 2022. Key observations include: 1) Total shares increased significantly from 17M to 47.2M over the period, 2) Accumulated deficit grew from -$1.01B to -$1.26B, 3) Despite growing losses, total stockholders' equity increased from $94M to $326M due to substantial capital raises through stock issuances, particularly in 2020 and 2021. The accompanying notes are an integral part of the financial statements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 88,
          "title": "Balance Sheet Details: Accrued Expenses, Deferred Tax Liabilities and Stockholders’ Equity",
          "data": [
            {
              "key": "Accrued payroll and employee benefits (2022 vs 2021)",
              "value": "7526K in 2022, down from 7968K in 2021"
            },
            {
              "key": "Accrued R&D contract costs (2022 vs 2021)",
              "value": "4223K in 2022, up from 2871K in 2021"
            },
            {
              "key": "Accrued professional fees (2022 vs 2021)",
              "value": "766K in 2022, compared to 878K in 2021"
            },
            {
              "key": "Other accrued expenses (2022 vs 2021)",
              "value": "320K in 2022, compared to 283K in 2021"
            },
            {
              "key": "Total accrued expenses",
              "value": "12835K in 2022 vs 12000K in 2021; a 7% increase year-over-year"
            },
            {
              "key": "Net deferred tax liabilities related to IPR&D (2022 vs 2021)",
              "value": "1613K unchanged; with total liabilities 6323K in 2022 vs 8908K in 2021"
            },
            {
              "key": "Deferred income from sale of tax benefits (2022)",
              "value": "4650K introduced in 2022 (was 0 in 2021)"
            },
            {
              "key": "Contingent milestones",
              "value": "0 in 2022 versus 6862K in 2021 (eliminated)"
            },
            {
              "key": "Deferred revenue",
              "value": "60K in 2022 versus 433K in 2021"
            },
            {
              "key": "Breakdown of current vs long-term portions",
              "value": "Current portion: -990K (2022), Long-term portion: 5333K (2022) versus -1554K and 7354K in 2021 respectively"
            },
            {
              "key": "New Jersey Tax Benefits Sale (March 2022)",
              "value": "Agreed to sell $5.0M in tax benefits for $4.7M; subject to maintaining a New Jersey base for five years or pro-rata repayment"
            },
            {
              "key": "New Jersey Tax Benefits Sale (November 2015)",
              "value": "Sold $9.8M in tax benefits for $9.2M; with $1.8M recorded as other income in 2020"
            },
            {
              "key": "Common Stock - Shelf Registration and Controlled Offerings",
              "value": "Filing of automatic shelf registration (Nov 2020) enabling sale of securities as needed"
            },
            {
              "key": "Equity Offering under Cantor Agreement (2020)",
              "value": "Issued 7,125,004 shares yielding net proceeds of $29.4M after commissions and expenses"
            },
            {
              "key": "Underwritten Public Offering (July 2021)",
              "value": "Issued 6,845,238 shares, net proceeds of $269.9M after underwriting fees"
            },
            {
              "key": "Underwritten Public Offering (June 2020)",
              "value": "Issued 15,384,614 shares, net proceeds of $141.4M after underwriting fees"
            },
            {
              "key": "Remaining Equity Offering Capacity (as of Dec 31, 2022)",
              "value": "$50M remaining under the November 2020 prospectus"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 99,
          "title": "Legal Documents and Lease Agreements Register",
          "data": [
            {
              "key": "3.8",
              "value": "Seventh Certificate of Amendment of Third Restated Certificate of Incorporation; Filing: 8-K (000-15006); Exhibit: 3.1; Date: 2/8/19"
            },
            {
              "key": "3.9",
              "value": "Second Amended and Restated By-Laws of Celldex Therapeutics, Inc.; Filing: 10-Q (000-15006); Exhibit: 3.1; Date: 11/9/22"
            },
            {
              "key": "4.1",
              "value": "Specimen of Common Stock Certificate; Filing: 8-K (000-15006); Exhibit: 41; Date: 2/8/19"
            },
            {
              "key": "4.2",
              "value": "Certificate of Designations, Preferences and Rights of Series C-1 Junior Participating Cumulative Preferred Stock; Filing: 8-A (000-15006); Exhibit: 3.1; Date: 11/8/04"
            },
            {
              "key": "4.3",
              "value": "Description of Securities; Filing: Filed herewith"
            },
            {
              "key": "10.1",
              "value": "Commercial Lease Agreement with Fourth Avenue Ventures; Filing: 10-Q/A (000-15006); Exhibit: 10.11; Date: 8/23/96"
            },
            {
              "key": "10.2",
              "value": "Extension of Lease Agreement with DIV Needham 53 LLC; Filing: 10-K (000-); Exhibit: 10.9; Date: 3/27/02"
            },
            {
              "key": "10.3",
              "value": "First Amendment to Lease with DIV Needham 115 LLC; Filing: 10-K; Exhibit: 10.40; Date: 3/16/06"
            },
            {
              "key": "10.4",
              "value": "Second Amendment to Lease with DIV Needham 115 LLC; Filing: 10-K/A (000-15006); Exhibit: 10.4; Date: 2/25/16"
            },
            {
              "key": "10.5",
              "value": "Lease Agreement with Massachusetts Development Finance Agency; Filing: 10-Q (000-15006); Exhibit: 10.1; Date: 4/30/04"
            },
            {
              "key": "10.6-10.11",
              "value": "First through Seventh Amendments to Massachusetts Development Finance Agency Lease; Filing: Various; Exhibit: Various; Date: 2005-2010"
            },
            {
              "key": "10.12",
              "value": "Eighth Amendment to Lease by and between the Company and University of Massachusetts Dartmouth dated as of November 1, 2015; Filing: 10-K/A (000-15006); Exhibit: 10.12; Date: 2/25/16"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 104,
          "title": "DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934",
          "data": [
            {
              "key": "Authorized Common Stock Shares",
              "value": "297,000,000 shares"
            },
            {
              "key": "Common Stock Par Value",
              "value": "$0.001 per share"
            },
            {
              "key": "Authorized Preferred Stock Shares",
              "value": "3,000,000 shares (including 350,000 Series C-1 Junior Participating Cumulative Preferred Stock)"
            },
            {
              "key": "Listing Symbol",
              "value": "CLDX on Nasdaq Capital Market"
            },
            {
              "key": "Dividend Policy",
              "value": "Board of Directors may declare dividends from legally available funds at any regular or special meeting, subject to rights of preferred stockholders"
            },
            {
              "key": "Voting Rights",
              "value": "One vote per common stock share; cumulative voting is not permitted"
            },
            {
              "key": "Liquidation Rights",
              "value": "In liquidation, common stockholders share equally in assets available after payment of debts and preferred stock liquidation preferences"
            },
            {
              "key": "Preemptive Rights",
              "value": "Common stockholders have no preemptive rights to subscribe for or acquire additional shares or related securities"
            },
            {
              "key": "Reference Documents",
              "value": "Third Restated Certificate of Incorporation and Amended and Restated By-Laws (Exhibit 4.3 of Form 10-K)"
            },
            {
              "key": "Governing Law",
              "value": "Delaware law may affect the terms of common stock"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 106,
          "title": "Exhibit 21.1 SUBSIDIARIES OF CELLDEX THERAPEUTICS, INC. Jurisdiction of Ownership",
          "data": [
            {
              "key": "Name",
              "value": "Celldex Therapeutics Switzerland GmbH"
            },
            {
              "key": "Organization",
              "value": "Switzerland"
            },
            {
              "key": "Percentage",
              "value": "100%"
            },
            {
              "key": "Summary",
              "value": "The table shows ownership information for Celldex Therapeutics Switzerland GmbH, indicating that it is a wholly-owned (100%) Swiss entity. This appears to be an ownership or subsidiary structure table typically found in corporate financial reports."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "mentions_new_risk_factors": {
      "value": true,
      "elements": [
        {
          "type": "risk_factor",
          "page": 3,
          "title": "Safe Harbor Statement and Forward-Looking Disclosures",
          "data": [
            {
              "key": "Document Description",
              "value": "Table of Contents for the Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 included in the Annual Report on Form 10-K."
            },
            {
              "key": "Regulatory Basis",
              "value": "Private Securities Litigation Reform Act of 1995; Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended."
            },
            {
              "key": "Forward-Looking Statements",
              "value": "Contains forward-looking statements related to beliefs, plans, objectives, goals, expectations, and future performance. Identified by words such as 'may', 'will', 'can', 'anticipate', 'assume', 'should', 'indicate', 'would', 'believe', 'contemplate', 'expect', 'seek', 'estimate', 'continue', 'plan', 'point to', 'project', 'predict', 'could', 'intend', 'target', 'potential'."
            },
            {
              "key": "Risk Factors Mentioned",
              "value": "Dependence on early stage product candidates; challenges in completing research and development including preclinical/clinical studies; timing for regulatory submissions and trial completions; ability to negotiate strategic partnerships; managing multiple clinical trials; costs and uncertainties of preclinical and clinical testing; expectations regarding product attributes (pharmaceutical properties, efficacy, safety, dosing); uncertainties in obtaining regulatory approvals; issues with supply and quality of clinical materials; commercialization challenges; competition; technological development; merger agreement obligations related to Kolltan Pharmaceuticals, Inc.; ability to raise sufficient capital."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 4,
          "title": "Table of Contents & Forward-Looking Statements",
          "data": [
            {
              "key": "Risk Factors",
              "value": "trials, discontinue or delay our commercial manufacturing efforts, discontinue or delay our efforts to expand into additional indications for our drug product candidates, license out programs earlier than expected, raise funds at significant discount or on other unfavorable terms, if at all, or sell all or part of our business; our ability to protect our intellectual property rights and our ability to avoid intellectual property litigation, which can be costly and divert management time and attention; our ability to develop and commercialize products without infringing the intellectual property rights of third parties; the impact of the COVID-19 pandemic on our business or on the economy generally; and the factors listed under “Risk Factors” in this Annual Report on Form 10-K."
            },
            {
              "key": "Forward-Looking Statements",
              "value": "All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this report or the date of the document incorporated by reference into this report. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 12,
          "title": "Risks from Partnership Termination and Competitive Landscape",
          "data": [
            {
              "key": "Partnership Termination Risk",
              "value": "Partnership agreements may terminate without benefit if the underlying products are not fully developed. Failure to meet obligations could lead to termination, delay commercialization, and incur additional time and financial costs."
            },
            {
              "key": "Collaboration Agreement Risk",
              "value": "Research collaboration and license agreements (e.g., with Yale University requiring a one-time $3.0 million payment and royalty payments) expose the company to risks in meeting milestones, partner performance, and potential early termination."
            },
            {
              "key": "Competitive Risk",
              "value": "The biotechnology and pharmaceutical industry is highly competitive, with numerous companies developing alternative or competing products, which could impact the successful commercialization of drug candidates."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 15,
          "title": "Risk Factors: Intellectual Property and Patent Challenges",
          "data": [
            {
              "key": "patent_uncertainty",
              "value": "There is no assurance that patent applications owned or licensed will result in granted patents or that granted patents will provide effective protection."
            },
            {
              "key": "third_party_patents",
              "value": "Third parties may secure patents that block the use or development of important technologies, impacting commercialization and further development."
            },
            {
              "key": "licensing_issues",
              "value": "Necessary licenses from third parties may be unattainable or only available under costly terms, potentially delaying or preventing product commercialization."
            },
            {
              "key": "litigation_risk",
              "value": "The business faces a heightened risk of intellectual property litigation, with potential challenges to patent validity and enforceability that may lead to substantial legal costs and operational disruptions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 16,
          "title": "Proprietary Rights, Government Regulation and FDA Approval Process",
          "data": [
            {
              "key": "Intellectual Property & Confidentiality",
              "value": "The document discusses reliance on unpatented technology, trade secrets, and confidential information, along with the use of confidentiality agreements with employees, consultants, and advisors to protect inventions and sensitive information. However, it notes that such agreements may not always provide meaningful protection against unauthorized use or disclosure."
            },
            {
              "key": "Government Regulation",
              "value": "The content emphasizes significant regulation by governmental bodies including the U.S. FDA and comparable international authorities, affecting manufacturing, testing, safety, labeling, documentation, advertising, and sale of products."
            },
            {
              "key": "FDA Approval Process",
              "value": "Describes the FDA regulatory framework including the need for preclinical studies, IND application before clinical trials, IRB approvals, adherence to good clinical practices (GCP), and the submission of NDA or BLA. It also highlights potential sanctions for non-compliance, such as application refusal, product recalls, fines, and other legal ramifications."
            },
            {
              "key": "Risk Implications",
              "value": "Failure to achieve regulatory approval or proper compliance could impair the company's ability to commercialize drug candidates, affecting future revenues."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 17,
          "title": "Регуляторные испытания и утверждение продуктов",
          "data": [
            {
              "key": "FDA Inspection",
              "value": "Проведение проверки производственных мощностей на соответствие требованиям cGMP для обеспечения качества и чистоты препарата."
            },
            {
              "key": "NDA/BLA Review",
              "value": "Ожидание утверждения NDA или BLA, рассматриваемых в качестве биологических продуктов, с учетом возможных задержек и изменений в регламентирующих политиках."
            },
            {
              "key": "Clinical Trials Process",
              "value": "Описание этапов клинических испытаний (Фазы 1, 2, 3) с упором на испытания безопасности, эффективности и оптимальной дозировки."
            },
            {
              "key": "Regulatory Approval Risks",
              "value": "Возможные задержки, неопределенности в интерпретации данных и неожиданные изменения в политике могут привести к задержке или даже отказу в утверждении продукта, что ограничит рынок."
            },
            {
              "key": "Impact on Commercialization",
              "value": "Любые задержки в клинических испытаниях или в процессе регуляторного утверждения могут негативно сказаться на коммерциализации продукта."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 18,
          "title": "FDA Regulatory Review and Approval Process",
          "data": [
            {
              "key": "FDA Review Process",
              "value": "The document outlines the FDA's evaluation process for NDA and BLA submissions, including facility inspections, clinical site reviews, and compliance with cGMP and GCP requirements."
            },
            {
              "key": "Approval Outcomes",
              "value": "It distinguishes between an approval letter, which permits commercial marketing with specific indications, and a complete response letter, which details deficiencies requiring further information or testing."
            },
            {
              "key": "Regulatory Risks",
              "value": "The text highlights risks such as delays, potential rejections, and added costs resulting from the lengthy and uncertain regulatory review process."
            },
            {
              "key": "Fast Track Designation",
              "value": "Explains the fast track program that expedites the review of drugs intended for serious conditions, including benefits like rolling review and more frequent FDA interactions."
            },
            {
              "key": "Priority Review",
              "value": "Describes the priority review designation which shortens the review time frame to six to eight months once a complete application is accepted."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 20,
          "title": "Regulatory Framework and Risk Factors Overview",
          "data": [
            {
              "key": "Regulatory Requirements",
              "value": "Drug and biologic manufacturers must register with the FDA and comply with cGMP standards. They are subject to periodic unannounced inspections and must obtain prior FDA approval for manufacturing changes."
            },
            {
              "key": "Compliance and Enforcement",
              "value": "FDA regulations require investigation and correction of deviations from cGMP, with potential consequences including product recalls, fines, warning letters, post-market clinical trials, and even criminal prosecution."
            },
            {
              "key": "Risk Evaluation and Mitigation Strategies",
              "value": "Non-compliance or emerging issues with manufacturing processes or adverse events can lead to revisions in approved labeling and other regulatory restrictions under risk mitigation programs."
            },
            {
              "key": "Biosimilars Law (BPCIA)",
              "value": "The act establishes an abbreviated approval pathway for biosimilars, including criteria for biosimilarity, exclusivity periods, and procedures for handling patent litigation."
            },
            {
              "key": "21st Century Cures Act",
              "value": "Passed in December 2016, this act is aimed at modernizing healthcare and spurring innovation with increased federal funding for FDA innovation projects and NIH research."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 21,
          "title": "Regulatory Risks and Companion Diagnostic Approval Process",
          "data": [
            {
              "key": "Cancer Moonshot Initiative Funding",
              "value": "The Cures Act authorizes funding for the 'Cancer Moonshot' initiative, aiming to stimulate drug development via a public-private partnership of 20 to 30 pharmaceutical and biotechnology companies."
            },
            {
              "key": "Companion Diagnostic Review",
              "value": "Drug candidates may rely on companion diagnostics that require separate FDA clearance through a costly, lengthy, and uncertain PMA process, supported by extensive technical, preclinical, clinical, and manufacturing data."
            },
            {
              "key": "PMA Process and Inspection",
              "value": "The PMA application process includes FDA pre-approval inspections of manufacturing facilities and may result in approval, approvable with conditions, or denial, impacting time to market."
            },
            {
              "key": "Regulatory Enforcement Risks",
              "value": "Non-compliance with FDA regulations and other federal/state laws can result in various enforcement actions such as fines, injunctions, recalls, or operational shutdowns, adversely affecting business operations."
            },
            {
              "key": "Fraud, Data Privacy and Transparency Laws",
              "value": "The company is subject to federal and state anti-kickback statutes, false claims laws, data privacy, and transparency regulations, which could lead to significant penalties if violated."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 22,
          "title": "Regulatory and Compliance Risks",
          "data": [
            {
              "key": "FCPA Compliance",
              "value": "Outlines the U.S. Foreign Corrupt Practices Act prohibiting payment or inducements to foreign officials to obtain or retain business, including interactions with healthcare professionals potentially meeting the definition of a foreign official."
            },
            {
              "key": "Foreign Regulatory Requirements",
              "value": "Describes the need to comply with a variety of regulatory requirements in foreign countries for marketing therapeutic or diagnostic products, including safety, efficacy, clinical trials, marketing authorization, and distribution."
            },
            {
              "key": "Approval Process Variability",
              "value": "Highlights that obtaining regulatory approval in foreign countries can involve extra testing, extended administrative reviews, and that approval in one country does not guarantee approval in another."
            },
            {
              "key": "EU Centralized Procedure",
              "value": "Explains that under the EU system, most marketing authorization applications will be submitted via a centralized procedure, which is mandatory for biotechnology-based medicines, cancer treatments, or orphan drugs."
            },
            {
              "key": "Orphan Drug Designation",
              "value": "Notes that orphan drug designation in the EU provides economic and marketing benefits, including a 10-year market exclusivity period for the approved indication."
            },
            {
              "key": "Third-Party Payor Coverage and Reimbursement",
              "value": "Discusses the uncertainty related to third-party payor coverage and reimbursement rates, which affects sales and could result in higher out-of-pocket costs for patients."
            },
            {
              "key": "Legislative and Regulatory Changes",
              "value": "Mentions that evolving legislation, revised FDA regulations, and policy changes could significantly impact product testing, approval processes, manufacturing, and marketing."
            },
            {
              "key": "Healthcare Cost Containment",
              "value": "Refers to the impact of initiatives like the Inflation Reduction Act and ongoing efforts by governments to contain healthcare costs, affecting drug pricing and reimbursement dynamics."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 23,
          "title": "Risk Factors Related to Drug Pricing, Reimbursement, and Cost-Effectiveness",
          "data": [
            {
              "key": "Medical Necessity and Cost-Effectiveness Evaluation",
              "value": "The document emphasizes that third-party payors assess the medical necessity and cost-effectiveness of products. If drugs are not deemed cost-effective compared to alternatives, coverage may be denied or reimbursed at lower levels."
            },
            {
              "key": "Risk of Limited Coverage and Reimbursement",
              "value": "There is a risk that, due to unfavorable cost-effectiveness assessments, drugs might not be covered or could face restrictions (such as formulary placement limitations), which would significantly impact projected sales volumes."
            },
            {
              "key": "Challenges in Negotiating Formulary Placement",
              "value": "Negotiations with hospitals, health systems, and independent delivery networks may be protracted and compromised by concerns over incremental medical benefits and cost-effectiveness."
            },
            {
              "key": "International Variability and Regulatory Pressures",
              "value": "Pricing and reimbursement schemes vary notably by country (e.g., EU vs. U.S.), including controls like fixed prices, rebates, and utilization restrictions, as well as legislative pressures that may further constrain pricing and coverage."
            },
            {
              "key": "Impact of Downward Pressure on Healthcare Costs",
              "value": "The document highlights a general downward pressure on healthcare costs, which adds to the risk of achieving favorable reimbursement and pricing arrangements for new drugs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 25,
          "title": "Table of Contents Item 1A. RISK FACTORS",
          "data": [
            {
              "key": "Section Overview",
              "value": "Discussion of risk factors material to the company, including forward-looking statements that could impact business, operations, financial condition, and cash flows."
            },
            {
              "key": "Risks Related to Financial Condition and Capital Requirements",
              "value": "Risks related to the need for additional capital, the Merger Agreement and related Settlement Agreement with Kolltan, and U.S. federal income tax reform."
            },
            {
              "key": "Risks Related to Drug Development and Regulatory Approval",
              "value": "Risks concerning funding and completion of R&D activities, obtaining regulatory approval for drug candidates, extensive regulatory scrutiny, and potential adverse side effects. Additionally, concerns over collaboration agreements for lead drug candidates."
            },
            {
              "key": "Risks Related to Commercialization",
              "value": "Risks involving delays, difficulties, or unanticipated costs in establishing sales, marketing and distribution capabilities, acceptance by physicians, patients and third-party payors, reimbursement decisions, and terms of FDA or foreign regulatory approvals."
            },
            {
              "key": "Risks Related to Reliance on Third Parties",
              "value": "Risks stemming from dependence on third parties."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 26,
          "title": "Table of Contents - Risks",
          "data": [
            {
              "key": "Risks Related to Business Operations",
              "value": "Risks related to strategic transactions; managing our growth; integrating and modifying technologies to create new drugs; computer systems and potential security breaches; hazardous materials; product liability claims; global economy and supply chain disruptions."
            },
            {
              "key": "Risks Related to Intellectual Property",
              "value": "Risks related to intellectual property."
            },
            {
              "key": "Regulatory Risks",
              "value": "Risks related to the regulatory approval process for our drugs; changes in product candidate manufacturing or formulation; compliance with laws and regulations."
            },
            {
              "key": "Risks Related to Our Capital Stock",
              "value": "Risks related to our history of losses, uncertainty of future profitability, volatility of our common stock, and use of net operating loss carryforwards."
            },
            {
              "key": "General Risk Factors",
              "value": "Risks related to internal controls over financial reporting; competitors may develop technologies that make ours obsolete; health epidemics and outbreaks; loss of key executives and scientists; employee misconduct; compliance with the Nasdaq Listing Rules."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 27,
          "title": "Risks Related to Our Financial Condition and Capital Requirements",
          "data": [
            {
              "key": "Product Revenue",
              "value": "Currently, no product revenue has been generated and there is uncertainty about future generation."
            },
            {
              "key": "Accumulated Deficit",
              "value": "$1.3 billion as of December 31, 2022."
            },
            {
              "key": "Operating Losses",
              "value": "Operating losses of $115.2 million in 2022, $71.2 million in 2021, and $63.4 million in 2020; expected to continue in 2023 and beyond."
            },
            {
              "key": "Clinical Trial Expense",
              "value": "$23.8 million in 2022, $8.0 million in 2021, and $4.9 million in 2020."
            },
            {
              "key": "Contract Manufacturing Expense",
              "value": "$4.5 million in 2022, $1.7 million in 2021, and $1.2 million in 2020."
            },
            {
              "key": "Cash and Marketable Securities",
              "value": "$305.0 million as of December 31, 2022."
            },
            {
              "key": "Capital Raising Needs",
              "value": "Additional capital will be required via licensing deals, possible business combinations, debt issuance, or equity offerings to fund operations and development."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 29,
          "title": "Regulatory Approval Process Risks",
          "data": [
            {
              "key": "Regulatory Scrutiny",
              "value": "Drug candidates are subject to extensive regulatory review by the FDA and comparable authorities internationally."
            },
            {
              "key": "Testing Process",
              "value": "The development process involves lengthy preclinical tests followed by Phase 1, Phase 2, and Phase 3 clinical trials, each with varying durations."
            },
            {
              "key": "Approval Requirement",
              "value": "Regulatory approval is required in all aspects including manufacture, testing, safety, and effectiveness before any drug candidate can be commercialized."
            },
            {
              "key": "Financial and Operational Risk",
              "value": "Failure to obtain approvals or demonstrate safety/efficacy at any testing phase could lead to significant setbacks and prevent future revenue generation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 30,
          "title": "Clinical Trial Enrollment and Execution Risks",
          "data": [
            {
              "key": "Patient Enrollment Challenges",
              "value": "Difficulties enrolling patients due to clinical test nature, patient population size, willingness for placebo, distance to trial sites, and strict eligibility criteria."
            },
            {
              "key": "Operational Delays",
              "value": "Risks of delays in commencing, enrolling, and completing clinical trials; potential increases in costs and even termination of testing."
            },
            {
              "key": "Contract and Supply Issues",
              "value": "Challenges in negotiating acceptable terms with contract research organizations and trial sites, as well as maintaining necessary supplies of study drug and comparator."
            },
            {
              "key": "Regulatory Risks",
              "value": "Possibility of regulatory disapproval, suspension, or termination of clinical research due to safety concerns, compliance issues, or inadequate trial data."
            },
            {
              "key": "Funding Challenges",
              "value": "Risk of inadequate funding or failure to secure partners to finance clinical trials, which could delay or halt development efforts."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 31,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Adverse_Side_Effects",
              "value": "Serious adverse or unacceptable side effects identified during drug candidate development can impede regulatory approval and market acceptance."
            },
            {
              "key": "Development_Risk",
              "value": "Potential for having to abandon or limit the development of drug candidates if unexpected safety issues arise."
            },
            {
              "key": "Clinical_Trial_Complexity",
              "value": "Late-stage clinical trials involve managing large patient populations and multiple sites, increasing operational complexity and resource requirements."
            },
            {
              "key": "Resource_Allocation",
              "value": "Limited financial and managerial resources may force prioritization of drug candidates with higher regulatory and commercial potential, possibly at the expense of other opportunities."
            },
            {
              "key": "Biologics_Immune_Response",
              "value": "Use of biologics can lead to immune-mediated reactions, including hypersensitivity, infusion-related reactions, and other severe side effects that affect safety and efficacy."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 32,
          "title": "Risk Factors: Clinical and Diagnostic Delays Impacting Drug Development",
          "data": [
            {
              "key": "Team Recruitment and Management",
              "value": "Decision between delaying the program or initiating it with inadequate management resources, which may lead to recruitment of inappropriate patients."
            },
            {
              "key": "Clinical Monitoring and Data Handling",
              "value": "Inadequate monitoring of clinical investigators and improper handling or analysis of data could compromise efficacy or safety conclusions."
            },
            {
              "key": "Companion Diagnostics Development",
              "value": "Failure to validate, develop, and obtain regulatory approval for companion diagnostics may adversely affect drug development strategy and delay regulatory approval for drug candidates."
            },
            {
              "key": "Regulatory Approval Delays",
              "value": "Delays or failures in obtaining FDA and other regulatory approvals could have a material adverse impact on commercialization timelines and future revenue generation."
            },
            {
              "key": "Competitive Market Risks",
              "value": "Intense competition and potential delays in reaching the market compared to competitors may reduce revenues from product sales."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 33,
          "title": "Risks Related to Commercialization of Our Drug Candidates",
          "data": [
            {
              "key": "collaborator_dependency",
              "value": "Reliance on collaborators to successfully develop and promote drug candidates; failure may require finding alternative partners."
            },
            {
              "key": "commercialization_challenges",
              "value": "Potential delays, difficulties, and unanticipated costs in establishing sales, marketing, and distribution capabilities or securing strategic partnerships."
            },
            {
              "key": "market_acceptance",
              "value": "Success dependent on proving product advantages over competitors and achieving acceptance among physicians, patients, and third-party payors."
            },
            {
              "key": "partnership_risk",
              "value": "Risk that strategic partnerships, co-promotion or licensing arrangements may not materialize or may be on unfavorable terms, reducing revenue potential."
            },
            {
              "key": "regulatory_approval_dependency",
              "value": "Even with FDA approval, commercialization success is not guaranteed due to potential challenges in marketing and distribution."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 34,
          "title": "Regulatory and Compliance Risks in Drug Development",
          "data": [
            {
              "key": "Market Acceptance",
              "value": "If future drugs fail to achieve market acceptance, significant revenues may not be generated and profitability could be affected."
            },
            {
              "key": "FDA Approval Conditions",
              "value": "Even with FDA approval, terms such as costly post-approval trials, warnings, contraindications, or REMS may limit commercial potential."
            },
            {
              "key": "Regulatory Compliance",
              "value": "Compliance with extensive regulatory requirements, including cGMP, labeling, packaging, distribution, and adverse event reporting, is critical. Failure may lead to sanctions, product recalls, or withdrawal of market approval."
            },
            {
              "key": "Operational Impact",
              "value": "Inability to comply with regulatory requirements may result in fines, injunctions, suspension of clinical studies, or import bans, impacting the business significantly."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 35,
          "title": "Reimbursement Impact on Drug Pricing and Market Acceptance",
          "data": [
            {
              "key": "Risk Description",
              "value": "Reimbursement decisions by third-party payors may adversely affect pricing, market acceptance, and overall commercialization of drug candidates."
            },
            {
              "key": "Key Factors",
              "value": "Government authorities and third-party payors may demand price discounts, rebates, and impose coverage limitations, which could reduce net prices and restrict market use."
            },
            {
              "key": "Operational Impact",
              "value": "The need for post-marketing studies to demonstrate cost-effectiveness can require significant management time and resources."
            },
            {
              "key": "Uncertainty",
              "value": "There is uncertainty about the availability and extent of reimbursement, which may affect the demand, pricing, and profitability of future drugs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 36,
          "title": "Regulatory Approval and International Operational Risks",
          "data": [
            {
              "key": "Regulatory Approval Delays",
              "value": "Failure or delay in obtaining regulatory approvals in foreign jurisdictions (including the EEA and other markets) may materially adversely affect sales and commercialization of drug candidates."
            },
            {
              "key": "Divergent Approval Processes",
              "value": "Approval procedures vary across countries, with different requirements and assessments (e.g., Marketing Authorization in the EEA versus FDA approval in the US), potentially leading to additional clinical testing and delays."
            },
            {
              "key": "International Market Risks",
              "value": "Risks associated with international operations include changes in tariffs, trade barriers, foreign currency fluctuations, economic instability, tax and employment regulation differences, and potential business interruptions due to geopolitical events or natural disasters."
            },
            {
              "key": "Impact on Commercialization",
              "value": "A failure to secure timely approvals can negatively affect both the domestic and international commercialization processes, possibly causing a broader adverse effect on business operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 37,
          "title": "Risks Related to Reliance on Third Parties",
          "data": [
            {
              "key": "Third Party Dependence",
              "value": "The document highlights the reliance on third parties for planning, conducting, and monitoring clinical tests, which if not performed to expected quality and timeliness, may lead to product development delays."
            },
            {
              "key": "Clinical Development Activities",
              "value": "Third parties are involved in essential activities including patient recruitment, trial monitoring, data management, safety monitoring, and project management. Their failure could delay or affect clinical studies."
            },
            {
              "key": "Contract Manufacturing Risks",
              "value": "There is reliance on CMOs for manufacturing drug substances and products, where issues such as cost variations, delivery, quality control, and regulatory non-compliance can lead to significant delays and commercialization risks."
            },
            {
              "key": "Scale-Up Challenges",
              "value": "Scaling up manufacturing for commercial quantities introduces technical challenges, quality assurance issues, and potential supply chain disruptions, which may require additional FDA validations and cause project delays."
            },
            {
              "key": "In-House vs. Third Party Manufacturing",
              "value": "While some manufacturing is done in-house at the Fall River facility, the reliance on third parties for other aspects increases the risk of delays due to manufacturing, compliance, or supply chain failures."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 38,
          "title": "Manufacturing Scale-Up and Third-Party Collaboration Risks",
          "data": [
            {
              "key": "ManufacturingScaleUp",
              "value": "The document highlights potential difficulties in scaling up manufacturing processes, including challenges with specialized manufacturing capabilities and securing reliable contract manufacturers."
            },
            {
              "key": "ForeignManufacturers",
              "value": "There are increased risks associated with relying on foreign manufacturers due to compliance issues with cGMP, language barriers, regulatory process unfamiliarity, supply chain issues, and geopolitical instability."
            },
            {
              "key": "ThirdPartyCollaborations",
              "value": "Dependence on third-party collaborators for developing and commercializing companion diagnostic tests introduces risks such as production delays, regulatory hurdles, and potential termination of partnerships."
            },
            {
              "key": "SupplyChainRisks",
              "value": "The discussion emphasizes risks related to supply disruptions, shipping delays, and changes in foreign regulatory laws that could impact timely manufacturing and commercialization."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 39,
          "title": "Risk Factors: Trade Secrets, Operational Disruptions and Strategic Transactions",
          "data": [
            {
              "key": "ThirdPartyDependency",
              "value": "Reliance on third parties requires sharing trade secrets, which increases the risk of competitors obtaining proprietary information."
            },
            {
              "key": "ConfidentialityAgreements",
              "value": "Use of confidentiality, material transfer, collaborative research, and consulting agreements to protect proprietary technology and restrict publication of sensitive data."
            },
            {
              "key": "OperationalRisk",
              "value": "Exposure to risks from natural disasters, infrastructure failures, and unplanned events that may disrupt manufacturing and lab facilities, adversely affecting business continuity."
            },
            {
              "key": "StrategicTransactions",
              "value": "Consideration of strategic transactions such as acquisitions, asset purchases, licensing deals, joint ventures, spin-offs, and restructurings which may incur substantial expenses and integration challenges."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 40,
          "title": "Risk Factors: Integration, Growth, and IT Security Challenges",
          "data": [
            {
              "key": "Increased Amortization Expenses",
              "value": "Higher expenses due to integration of acquired businesses impacting financial performance."
            },
            {
              "key": "Integration Difficulties",
              "value": "Challenges and costs associated with combining operations and personnel of acquired businesses."
            },
            {
              "key": "Supplier/Customer Relationship Impairment",
              "value": "Risk that changes in management and ownership could damage relationships with key suppliers and customers of acquired businesses."
            },
            {
              "key": "Retention of Key Employees",
              "value": "Potential inability to retain essential staff from acquired businesses."
            },
            {
              "key": "Growth Management Challenges",
              "value": "Risks associated with expanding clinical development, regulatory, and commercial capabilities, including managing increased headcount and operational scope."
            },
            {
              "key": "Integration of Acquired/Licensed Technologies",
              "value": "Risk of not successfully integrating new assets and licensed technologies, which could result in lost investments and competitive disadvantages."
            },
            {
              "key": "IT and Cybersecurity Risks",
              "value": "Vulnerabilities in internal computer systems and those of partners could lead to disruptions in drug development programs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 41,
          "title": "Risk Factors: Operational, Regulatory & Supply Chain Disruptions",
          "data": [
            {
              "key": "Operational Disruption",
              "value": "Loss of clinical trial data, cybersecurity breaches, or interruptions in operations could delay drug development programs and regulatory approvals."
            },
            {
              "key": "Regulatory Compliance Risk",
              "value": "Strict laws and regulations such as HIPAA, GDPR, and other state and federal requirements may impose significant liability and increased costs if not complied with."
            },
            {
              "key": "Environmental & Safety Risk",
              "value": "Use of hazardous materials and biological substances entails risks of accidental contamination or injury, along with ongoing environmental compliance costs."
            },
            {
              "key": "Product Liability Risk",
              "value": "Exposure to product liability claims and potential recalls may result in substantial financial losses and negative publicity."
            },
            {
              "key": "Supply Chain Disruption Risk",
              "value": "Global economic disruptions and supply chain interruptions have led to longer lead times and increased costs for critical components."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 42,
          "title": "Risk Factors: Supply Chain and Intellectual Property",
          "data": [
            {
              "key": "Supply Chain Risks",
              "value": "Unforeseen global supply chain events and inflationary pressures may have a material adverse effect on the business, financial condition, and operations."
            },
            {
              "key": "Intellectual Property Licensing",
              "value": "Risks include noncompliance with licensing obligations, potential loss of license rights, and the requirement to meet milestones or resource commitments imposed by licensors."
            },
            {
              "key": "Patent Protection Challenges",
              "value": "The ability to obtain and enforce broad patents is uncertain, which may allow competitors to use similar technologies or challenge existing patents."
            },
            {
              "key": "R&D and Commercialization Risks",
              "value": "The need to prioritize and sometimes slow down or cease activities in research and development may jeopardize fulfilling licensing obligations, adversely affecting product development."
            },
            {
              "key": "Litigation and Legal Costs",
              "value": "Potential disputes over intellectual property rights could result in costly litigation, challenges to patent validity, and the need to negotiate less favorable licensing terms."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 43,
          "title": "Intellectual Property and Trade Secrets Risks",
          "data": [
            {
              "key": "Topic",
              "value": "Risks related to intellectual property licenses, trade secrets, and potential litigation."
            },
            {
              "key": "License Availability",
              "value": "Licenses for essential third-party patents or proprietary technology may not be available or may be on unfavorable terms."
            },
            {
              "key": "Trade Secrets",
              "value": "Risk of misappropriation or inadvertent disclosure of trade secrets and confidential information."
            },
            {
              "key": "Litigation Risk",
              "value": "Potential for costly and time-consuming lawsuits regarding patent infringement and intellectual property disputes."
            },
            {
              "key": "Competitive Impact",
              "value": "Infringement claims and breaches of confidentiality could harm business operations and competitive positioning."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 44,
          "title": "Litigation and Regulatory Risks",
          "data": [
            {
              "key": "Litigation Risk",
              "value": "Potential litigation to defend against claims from former employers or third parties, which may lead to monetary damages, loss of intellectual property rights, or personnel."
            },
            {
              "key": "Regulatory Risk - Orphan Drug Designation",
              "value": "Risk of not obtaining or maintaining orphan drug designation or exclusivity for product candidates, which could affect market exclusivity and financial incentives under the Orphan Drug Act."
            },
            {
              "key": "Market Exclusivity Details",
              "value": "If granted, orphan drug designation provides a period of marketing exclusivity (7 years in the US and up to 10 years in Europe, potentially reduced under certain conditions), but this exclusivity can be lost under various circumstances."
            },
            {
              "key": "Risk of Fast Track, Priority Review, and Breakthrough Therapy Designations",
              "value": "Even if designations for fast track, priority review, or breakthrough therapy are granted, they do not guarantee faster development, review, or approval, and may be withdrawn if not supported by clinical data."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 45,
          "title": "Risk Factors in Regulatory Approval and Clinical Trials",
          "data": [
            {
              "key": "Breakthrough Therapy Designation",
              "value": "Designation is at the FDA's discretion and does not guarantee a faster development, review, or ultimate approval process."
            },
            {
              "key": "Regulatory Compliance",
              "value": "Non-compliance with FDA and other regulatory requirements in clinical trials and manufacturing could result in delays or restrictions in obtaining drug approvals."
            },
            {
              "key": "International Clinical Trials",
              "value": "Reliance on data from foreign clinical trials poses risks due to differences in regulatory compliance, potential for data rejection by the FDA, and the need for onsite inspections."
            },
            {
              "key": "Operational and Financial Risks",
              "value": "Additional risks include administrative burdens, foreign currency fluctuations, and the potential for unexpected issues in approved products or manufacturing processes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 46,
          "title": "Regulatory and Manufacturing Risk Factors",
          "data": [
            {
              "key": "Overview",
              "value": "The document outlines various risks associated with changes in manufacturing processes and product candidate formulations. These changes may result in increased costs, delays in clinical trials, and potential differences in product performance."
            },
            {
              "key": "Regulatory Impact",
              "value": "Increased regulatory obligations and continued review by FDA, EMA, and other authorities may lead to additional testing, bridging trials, or even suspension of manufacturing and clinical studies if non-compliance or issues are discovered."
            },
            {
              "key": "Compliance Risks",
              "value": "Non-compliance with cGMP regulations and other safety and quality standards may lead to sanctions such as warning letters, fines, product recalls, or withdrawal of regulatory approvals."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 48,
          "title": "Compliance with Privacy and Security Regulations Overview",
          "data": [
            {
              "key": "Regulatory Compliance Challenges",
              "value": "Compliance with diverse domestic and international privacy and security regulations (e.g., HIPAA, GDPR, state laws) creates complex and costly compliance challenges."
            },
            {
              "key": "Health Information Regulations",
              "value": "Personal and health information management is subject to strict regulations, requiring specific safeguards and explicit consent in some regions."
            },
            {
              "key": "Legislative Risk",
              "value": "Evolving legislative frameworks such as the ACA and the Inflation Reduction Act introduce uncertainty and potential adverse impacts on drug approvals, pricing, and profitability."
            },
            {
              "key": "Penalty Exposure",
              "value": "Non-compliance with applicable laws could result in significant civil and criminal penalties along with reputational harm."
            },
            {
              "key": "Operational Impact",
              "value": "The complexity and potential conflicts between various regulations may force changes in business practices and incur additional costs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 49,
          "title": "Table of Contents Risks Related to Our Capital Stock",
          "data": [
            {
              "key": "Investment Risk",
              "value": "Our common stock is considered a highly speculative investment due to a history of losses and uncertainty in future profitability."
            },
            {
              "key": "Revenue",
              "value": "No commercial revenue has been generated to date from sales of our drug candidates."
            },
            {
              "key": "Accumulated Deficit",
              "value": "The company had an accumulated deficit of $1.3 billion as of December 31, 2022."
            },
            {
              "key": "R&D Investment",
              "value": "Substantial funds are expected to be spent on further research and development testing of our drug candidates."
            },
            {
              "key": "FDA Approval Preparations",
              "value": "Upon FDA approval, significant investments will be needed to establish sales, marketing, quality control, regulatory compliance, and commercial manufacturing alliances."
            },
            {
              "key": "Profitability Concerns",
              "value": "The company may continue to lose money for several years, with uncertainty about achieving sustained profitability, which could affect operations and capital-raising ability."
            },
            {
              "key": "Market Volatility",
              "value": "Historically, the market price of the common stock has experienced significant volatility, with quoted examples ranging from a high of $57.20 to a low of $15.37."
            },
            {
              "key": "Litigation Risk",
              "value": "Potential securities class action litigation due to stock price volatility could incur substantial costs and divert management resources."
            },
            {
              "key": "Net Operating Loss Carryforwards",
              "value": "As of December 31, 2022, federal NOL carryforwards of approximately $623.1 million and state NOLs of approximately $879.9 million exist, subject to limitations under Section 382 and similar state provisions."
            },
            {
              "key": "Ownership Changes",
              "value": "Previous ownership changes (in October 2007, June 2009, December 2009, and December 2013) may impose annual limitations on the utilization of NOL and tax credit carryforwards."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 50,
          "title": "Income Taxes, Ownership Change Effects, and General Risk Factors",
          "data": [
            {
              "key": "Tax Effects",
              "value": "Discussion on assets at the time of ownership change, unrealized gains/losses, net operating loss (NOL) carryforwards, and implications of Tax Cuts and Jobs Act and CARES Act."
            },
            {
              "key": "Internal Control Risk",
              "value": "Risk factors related to maintaining effective internal controls over financial reporting and the consequences of control deficiencies."
            },
            {
              "key": "Competitive Risks",
              "value": "Risks arising from intense competition in the biotechnology and pharmaceutical industries, including potential competitive product developments and regulatory challenges."
            },
            {
              "key": "Pandemic Impact",
              "value": "Uncertainties related to health epidemics such as COVID-19 and their potential to disrupt preclinical studies and clinical trials."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 51,
          "title": "Risk Factors: COVID-19 Impact and Operational Risks",
          "data": [
            {
              "key": "COVID-19 Restrictions",
              "value": "Government-imposed travel restrictions and business closures are adversely impacting operations."
            },
            {
              "key": "Clinical Trial Delays",
              "value": "Enrollment and progress of clinical and preclinical trials may be delayed due to the pandemic and impacted regulatory approvals."
            },
            {
              "key": "Third-Party Dependency",
              "value": "Reliance on independent clinical investigators, contract research organizations, and third-party suppliers may be compromised, leading to delays in API and drug product delivery."
            },
            {
              "key": "Workforce and Personnel Risks",
              "value": "Employee availability, retention of key executives and skilled staff, and the risks of employee misconduct could adversely affect trial progress and overall operations."
            },
            {
              "key": "Regulatory and Legal Risks",
              "value": "Potential noncompliance with regulatory standards, risk of fraud or misconduct, and subsequent fines or sanctions may have significant negative effects on the business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 52,
          "title": "Listing Rules Compliance Risk and Property Details",
          "data": [
            {
              "key": "Listing Rules Compliance Risk",
              "value": "The document details concerns about maintaining compliance with the NASDAQ Listing Rules, including the minimum bid price requirement. Failure to meet these requirements could lead to delisting, negatively impacting the market price, liquidity, and capital raising ability."
            },
            {
              "key": "Leased Properties Summary",
              "value": "A table is provided listing significant leased properties located in Hampton, New Jersey; Fall River, Massachusetts; and New Haven, Connecticut. The properties range from 17,700 to 33,900 square feet with lease expiration dates in 2025, although some typographical errors in dates and location names are noted. The leases include renewal options."
            },
            {
              "key": "Legal Proceedings",
              "value": "The company is not currently a party to any material legal proceedings."
            },
            {
              "key": "Mine Safety Disclosures",
              "value": "Not applicable."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 96,
          "title": "Changes in Internal Control Over Financial Reporting",
          "data": [
            {
              "key": "Internal Control Changes",
              "value": "There were no changes in our internal control over financial reporting during the three months ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting."
            },
            {
              "key": "Other Information",
              "value": "None"
            },
            {
              "key": "Foreign Jurisdictions Disclosure",
              "value": "Not applicable"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_guidance_updates": {
      "value": false,
      "elements": []
    },
    "has_regulatory_or_litigation_issues": {
      "value": true,
      "elements": [
        {
          "type": "regulatory_litigation",
          "page": 19,
          "title": "Table of Contents for FDA Regulatory Pathways",
          "data": [
            {
              "key": "Priority Review Eligibility",
              "value": "Drugs or biologics may receive priority review if they provide a significant improvement compared to marketed products in treatment, diagnosis or prevention of disease. This includes products regulated by FDA’s Center for Biologics Evaluation and Research (CBER)."
            },
            {
              "key": "Accelerated Approval",
              "value": "Under accelerated approval regulations, a drug or biologic for a serious or life-threatening illness may be approved based on a surrogate endpoint likely to predict clinical benefit, with strict post-marketing compliance including Phase 4 trials."
            },
            {
              "key": "Breakthrough Therapy Designation",
              "value": "This designation expedites development and review for drugs intended to treat serious conditions where preliminary clinical evidence indicates substantial improvement over existing therapies on clinically significant endpoints."
            },
            {
              "key": "Orphan Drug Designation",
              "value": "For drugs intended to treat rare diseases (affecting fewer than 200,000 individuals in the US), orphan designation provides benefits such as a seven-year exclusive marketing period, tax credits, and waiver of application fees, but does not shorten the regulatory review process."
            },
            {
              "key": "Pediatric Information",
              "value": "Under the Pediatric Research Equity Act, applications must contain adequate data to assess safety and effectiveness in all relevant pediatric subpopulations, though deferrals or waivers may be granted in certain cases."
            },
            {
              "key": "Post Approval Requirements",
              "value": "After FDA approval, products are subject to extensive post-marketing regulation including recordkeeping, periodic reporting, and additional testing (e.g., Phase 4 trials) to confirm clinical benefits."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 47,
          "title": "Regulatory Compliance and Risk Disclosure",
          "data": [
            {
              "key": "Operational Restrictions",
              "value": "Restrictions on operations including costly new manufacturing requirements, seizure or detention of drugs, and import bans."
            },
            {
              "key": "Regulatory Compliance",
              "value": "Obligations to comply with federal and state healthcare fraud and abuse laws, false claims laws, privacy and security laws (HIPAA, HITECH), and transparency requirements under the ACA and Physician Sunshine Act."
            },
            {
              "key": "Potential Penalties",
              "value": "Non-compliance may result in substantial penalties such as exclusion from federal healthcare programs, civil and criminal penalties, fines, damages, and potential curtailment or restructuring of operations."
            },
            {
              "key": "Legal and Regulatory Risk",
              "value": "The text highlights uncertainty regarding future government regulations and the inability to predict the likelihood or extent of regulatory actions, which may adversely impact marketing of products and overall business operations."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_strategic_restructuring": {
      "value": true,
      "elements": [
        {
          "type": "strategic_restructuring",
          "page": 100,
          "title": "Ninth Amendment to Lease by and between the Company and University of Massachusetts Dartmouth dated as of October 1, 2019",
          "data": [
            {
              "key": "document_id",
              "value": "10.13"
            },
            {
              "key": "filing_type",
              "value": "10 (000- -K 5006)"
            },
            {
              "key": "exhibit",
              "value": "10.13"
            },
            {
              "key": "date",
              "value": "3/26/20"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "strategic_restructuring",
          "page": 100,
          "title": "Tenth Amendment to Lease by and between the Company and University of Massachusetts Dartmouth dated as of August 1, 2022",
          "data": [
            {
              "key": "document_id",
              "value": "10.14"
            },
            {
              "key": "filing_type",
              "value": "10 (000- -Q 5006)"
            },
            {
              "key": "exhibit",
              "value": "0.2"
            },
            {
              "key": "date",
              "value": "11/9/22"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "strategic_restructuring",
          "page": 100,
          "title": "Lease Agreement dated as of May 1, 2013 by and between Crown Perryville, LLC and the Company.",
          "data": [
            {
              "key": "document_id",
              "value": "10.15"
            },
            {
              "key": "filing_type",
              "value": "10 (000- -Q 5006)"
            },
            {
              "key": "exhibit",
              "value": "0.1"
            },
            {
              "key": "date",
              "value": "5/03/13"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "strategic_restructuring",
          "page": 100,
          "title": "First Amendment to Lease between Company and Crown Perryville, LLC dated as of June 17, 2015",
          "data": [
            {
              "key": "document_id",
              "value": "10.16"
            },
            {
              "key": "filing_type",
              "value": "10 (000- -Q 5006)"
            },
            {
              "key": "exhibit",
              "value": "0.2"
            },
            {
              "key": "date",
              "value": "8/10/15"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "strategic_restructuring",
          "page": 100,
          "title": "Second Amendment to Lease Agreement between the Company and Crown Perryville, LLC dated as of March 8, 2019",
          "data": [
            {
              "key": "document_id",
              "value": "10.17"
            },
            {
              "key": "filing_type",
              "value": "10 (000- -Q 5006)"
            },
            {
              "key": "exhibit",
              "value": "0.1"
            },
            {
              "key": "date",
              "value": "5/7/19"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "strategic_restructuring",
          "page": 100,
          "title": "Third Amendment to Lease Agreement between the Company and Perryville SPE LLC (successor-in- interest) to Crown Perryville, LLC dated as of May 23, 2022",
          "data": [
            {
              "key": "document_id",
              "value": "10.18"
            },
            {
              "key": "filing_type",
              "value": "10 (000- -Q 5006)"
            },
            {
              "key": "exhibit",
              "value": "0.3"
            },
            {
              "key": "date",
              "value": "8/8/22"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "strategic_restructuring",
          "page": 100,
          "title": "Extension of Lease Agreement between the Company and University of Massachusetts Dartmouth dated as of July 1,_2020",
          "data": [
            {
              "key": "document_id",
              "value": "10.19"
            },
            {
              "key": "filing_type",
              "value": "10-Q (000- 15006)"
            },
            {
              "key": "exhibit",
              "value": "10.1"
            },
            {
              "key": "date",
              "value": "8/6/20"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "strategic_restructuring",
          "page": 100,
          "title": "Contracts-Stock and Credit Amended and Restated License Agreement by and between the Company and Yale University dated as of July 26, 2022",
          "data": [
            {
              "key": "document_id",
              "value": "*10.20"
            },
            {
              "key": "filing_type",
              "value": "10-Q (000- 15006)"
            },
            {
              "key": "exhibit",
              "value": "10.1"
            },
            {
              "key": "date",
              "value": "11/9/22"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "strategic_restructuring",
          "page": 100,
          "title": "Purchase, Financing Agreements Sales Agreement, dated May 19, 2016, by and between Celldex Inc. and Cantor & Co.",
          "data": [
            {
              "key": "document_id",
              "value": "10.21"
            },
            {
              "key": "filing_type",
              "value": "8 -K"
            },
            {
              "key": "exhibit",
              "value": "1.1"
            },
            {
              "key": "date",
              "value": "5/19/16"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "strategic_restructuring",
          "page": 100,
          "title": "Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan",
          "data": [
            {
              "key": "document_id",
              "value": "10.22"
            },
            {
              "key": "filing_type",
              "value": "8-K (000- 5006)"
            },
            {
              "key": "exhibit",
              "value": "0.1"
            },
            {
              "key": "date",
              "value": "6/17/21"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_supply_chain_disruptions": {
      "value": true,
      "elements": [
        {
          "type": "supply_chain_disruption",
          "page": 14,
          "title": "Table of Contents – Supply Chain and Operational Risks",
          "data": [
            {
              "key": "third_party_manufacturers_control",
              "value": "Use of third-party manufacturers limits control and monitoring over manufacturing processes, which could lead to undetected problems."
            },
            {
              "key": "additional_costs_and_delays",
              "value": "Potential delays and additional costs may arise if third-party manufacturers fail to meet manufacturing needs or comply with regulatory requirements."
            },
            {
              "key": "manufacturing_capacity_risk",
              "value": "Difficulty in having multiple manufacturers ready to supply needed materials without incurring significant costs."
            },
            {
              "key": "commercial_experience",
              "value": "Mention of limited commercial experience in marketing, sales, distribution and product reimbursement."
            },
            {
              "key": "intellectual_property_strategy",
              "value": "Discussion of patents, licenses, and proprietary rights aimed at protecting technology and competitive position."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_esg_initiatives": {
      "value": false,
      "elements": []
    }
  },
  "currency": {
    "USD": 18,
    "EUR": 13,
    "AUD": 6,
    "CAD": 4,
    "ZAR": 3,
    "RUB": 1
  },
  "sha1": "2cdfd39bbf896b0f6651ebb0fe697cdf8c7ef0e8"
}